<!DOCTYPE html
  PUBLIC "-//W3C//DTD HTML 4.01//EN">
<html xmlns:gc="http://docs.oasis-open.org/codelist/ns/genericode/1.0/"><head xmlns="http://www.w3.org/1999/xhtml"><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"></meta><meta charset="utf-8"></meta><meta name="viewport" content="width=device-width, initial-scale=1"></meta><meta http-equiv="X-UA-Compatible" content="IE=10"></meta><meta name="documentId" content="e24f574b-7e12-4374-b010-b808e0b108aa"></meta><meta name="documentSetId" content="ac9c8e28-2798-4134-8197-2b249d836002"></meta><meta name="documentVersionNumber" content="3"></meta><meta name="documentEffectiveTime" content="20180101"></meta><title>LORUM IPSUM (acetaminophen), TABLET, CAPSULE, POWDER</title><link href="http://canada.ca/etc/designs/canada/wet-boew/assets/favicon.ico" rel="icon" type="image/x-icon"> </link><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.4.1/css/bootstrap.min.css" integrity="sha384-Vkoo8x4CGsO3+Hhxv8T/Q5PaXtkKtu6ug5TOeNV6gBiFeWPGFN9MuhOf23Q9Ifjh" crossorigin="anonymous"> </link><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"> </link><link rel="stylesheet" href="https://healthcanada.github.io/HPFB/product-monograph/style-sheet/spl_canada.css"> </link><style>
				/* ScrollSpy, Stickiness/Affix, and French Navigation Reduction */								
				.sticky {
					position: -webkit-sticky;
					position: sticky;
					top: 0;
				}
				
				
				</style></head><body data-spy="scroll" data-target="#navigation-sidebar" data-offset="1"><div class="bg-aurora-accent1 hide-in-print" id="header"><h2 class="text-white text-center p-2">LORUM IPSUM (acetaminophen), TABLET, CAPSULE, POWDER</h2></div><div class="container-fluid position-relative" id="content"><div class="row h-100"><aside xmlns="http://www.w3.org/1999/xhtml" class="hide-in-print mb-2" id="left"><div class="sticky-top sticky d-none d-md-block hide-in-print" id="side"><section class="card"><h5 class="card-header text-white bg-aurora-accent1">TABLE OF CONTENTS</h5><div style="transform: scaleX(-1);" id="navigation-scrollbar"><ul class="navbar-nav" id="navigation-sidebar" style="transform: scaleX(-1); "><li class="nav-top">Sections or subsections that are not applicable at the time of authorization are not listed.</li><li class="nav-item"><a href="#drop-bdeefc11-4315-41e3-8c56-83e8bf4f770b" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PRODUCT DETAILS</a><ul id="drop-bdeefc11-4315-41e3-8c56-83e8bf4f770b" class="navbar-nav small collapse"><li class="nav-item"><a href="#company-details" class="nav-link active">COMPANY DETAILS</a></li><li class="nav-item"><a href="#product-1" class="nav-link">Product #1 LORUM IPSUM TABLETS 
		(acetaminophen), 		
			
			ACETAMINOPHEN&nbsp;
				100&nbsp;								
			mg&nbsp;
			/ ACEXAMIC ACID&nbsp;
				45&nbsp;								
			mg&nbsp;
			Tablet</a></li><li class="nav-item"><a href="#product-2" class="nav-link">Product #2 LORUM IPSUM CAPSULE 
		(acetaminophen), 		
			
			ACETAMINOTADALAFIL&nbsp;
				200&nbsp;								
			mg&nbsp;
			/ ACETAMINOPHEN&nbsp;
				50&nbsp;								
			mg&nbsp;
			Capsule, hard</a></li><li class="nav-item"><a href="#product-3" class="nav-link">Product #3 LORUM IPSUM POWDER 
		(acetaminophen), 		
			
			ACETAMINOPHEN&nbsp;
				1&nbsp;								
			mg&nbsp;
			Powder for oral solution</a></li><li class="nav-item"><a href="#product-4" class="nav-link">Product #4 LORUM IPSUM 
		(acetaminophen)</a></li><li class="nav-item"><a href="#product-5" class="nav-link">Product #5 LORUM IPSUM CELLS RANGE 
		(acetaminophen), 		
			
			ACETAMINOPHEN&nbsp;
				2,000,000&nbsp;-&nbsp;60,000,000&nbsp;								
			CELLS&nbsp;
			Solution for injection</a></li></ul></li><li class="nav-item"><a href="#eed00b53-cdb2-4aa6-9e82-88b7d793b208" class="nav-link nav-top">TITLE PAGE</a></li><li class="nav-item"><a href="#dd1e1c43-f0d3-4ba8-b1f5-bd009a5dd5a8" class="nav-link nav-top">NOTICE OF COMPLIANCE WITH CONDITIONS</a></li><li class="nav-item"><a href="#dd1e1c93-f0d3-4ba8-b1f5-ad009a5dd5a8" class="nav-link nav-top">RECENT MAJOR LABEL CHANGES</a></li><li class="nav-item"><a href="#dd1e1c41-f0d3-4ba8-b1f5-bd009a5dd5a8" class="nav-link nav-top">BIOSIMILAR BIOLOGIC DRUG</a></li><li class="nav-item"><a href="#drop-e6bb83b9-2602-4f96-9077-b8b9535c254e" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PART I: HEALTH PROFESSIONAL INFORMATION</a><ul id="drop-e6bb83b9-2602-4f96-9077-b8b9535c254e" class="navbar-nav small collapse"><li class="nav-item"><a href="#c2ea4fad-2b79-4dbc-8d99-6843adc2dec8" class="nav-link">1 INDICATIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#f2aa7e0e-2042-4a4c-a783-9ad4e8717a32" class="nav-link">1.1 Pediatrics</a></li><li class="nav-item"><a href="#be75cfb9-3132-4903-800b-267427388a13" class="nav-link">1.2 Geriatrics</a></li></ul></li><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-367427388a13" class="nav-link">2 CONTRAINDICATIONS</a></li><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-267427398a13" class="nav-link">3 SERIOUS WARNINGS AND PRECAUTIONS BOX</a></li><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-267727398a13" class="nav-link">4 DOSAGE AND ADMINISTRATION</a><ul class="navbar-nav"><li class="nav-item"><a href="#be75cfb9-3131-4103-800b-267727398a13" class="nav-link">4.1 Dosing Considerations</a></li><li class="nav-item"><a href="#b3d876c1-c36c-4ed5-8993-c507e3ab9f2e" class="nav-link">4.2 Recommended Dose and Dosage Adjustment</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f4a" class="nav-link">4.3 Reconstitution</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f3a" class="nav-link">4.4 Administration</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f5a" class="nav-link">4.5 Missed Dose</a></li><li class="nav-item"><a href="#a63c98a5-e08a-472c-b8a2-a12dba105a5a" class="nav-link">4.6 Image Acquisition and Interpretation</a></li><li class="nav-item"><a href="#a63c98a5-e08a-472c-b8a2-a12dba105f5a" class="nav-link">4.7 Instructions for Preparation and Use</a></li><li class="nav-item"><a href="#a63c08a5-e08a-472c-b8a2-a12dba105f5a" class="nav-link">4.8 Radiation Dosimetry</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f6a" class="nav-link">5 OVERDOSAGE</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f7a" class="nav-link">6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c98a5-e08a-400c-b8a2-a12dba105f5a" class="nav-link">6.1 Physical Characteristics</a></li><li class="nav-item"><a href="#a63c90a5-e08a-400c-b8a2-a12dba105f5a" class="nav-link">6.2 External Radiation</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba115f7a" class="nav-link">7 WARNINGS AND PRECAUTIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dbc115f7a" class="nav-link">7.1 Special Populations</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b12dbc115f7a" class="nav-link">7.1.1 Pregnant Women</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b12dbd115f7a" class="nav-link">7.1.2 Breast-feeding</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8c2-b12dbc115f7a" class="nav-link">7.1.3 Pediatrics</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8d2-b12dbc115f7a" class="nav-link">7.1.4 Geriatrics</a></li></ul></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b22dbc115f7a" class="nav-link">8 ADVERSE REACTIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b12dbd215f7a" class="nav-link">8.1 Adverse Reaction Overview</a></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b12dbd215f7a" class="nav-link">8.2 Clinical Trial Adverse Reactions</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b12d0d215f7a" class="nav-link">8.2.1 Clinical Trial Adverse Reactions - Pediatrics</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b12dbd315f7a" class="nav-link">8.3 Less Common Clinical Trial Adverse Reactions</a><ul class="navbar-nav"><li class="nav-item"><a href="#a63c33a5-e08a-465c-b8a2-b12d0d215f7a" class="nav-link">8.3.1 Less Common Clinical Trial Adverse Reactions - Pediatrics</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b22dbd215f7a" class="nav-link">8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data</a></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b32dbd215f7a" class="nav-link">8.5 Post-Market Adverse Reactions</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-483c-b8a2-b22dbd215f7a" class="nav-link">9 DRUG INTERACTIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-267527398a13" class="nav-link">9.1 Serious Drug Interactions</a></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b14dbd315f7a" class="nav-link">9.2 Drug Interactions Overview</a></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8d2-b14dbd315f7a" class="nav-link">9.3 Drug-Behavioural Interactions</a></li><li class="nav-item"><a href="#a63c33a5-e0aa-473c-b8a2-b14dbd315f7a" class="nav-link">9.4 Drug-Drug Interactions</a></li><li class="nav-item"><a href="#a63c33a5-e08a-47bc-b8d2-b14dbd315f7a" class="nav-link">9.5 Drug-Food Interactions</a></li><li class="nav-item"><a href="#be78cfb9-3131-4903-800b-267527398a13" class="nav-link">9.6 Drug-Herb Interactions</a></li><li class="nav-item"><a href="#a63c33a5-e0aa-473c-b8a2-b14dcd315f7a" class="nav-link">9.7 Drug-Laboratory Test Interactions</a></li></ul></li><li class="nav-item"><a href="#fa324c26-b939-4c3a-901d-516ccc314522" class="nav-link">10 CLINICAL PHARMACOLOGY</a><ul class="navbar-nav"><li class="nav-item"><a href="#f7a324c26-b939-4c3a-901e-516ccc314522" class="nav-link">10.1 Mechanism of Action</a></li><li class="nav-item"><a href="#da324c26-b939-4d3a-901e-516ccc314522" class="nav-link">10.2 Pharmacodynamics</a></li><li class="nav-item"><a href="#aaa324c26-b939-4d4a-901e-516ccc314522" class="nav-link">10.3 Pharmacokinetics</a></li></ul></li><li class="nav-item"><a href="#da324d26-c939-443a-901e-526dcc314522" class="nav-link">11 STORAGE, STABILITY AND DISPOSAL</a></li><li class="nav-item"><a href="#bba325d26-c939-443a-901e-526dcc314522" class="nav-link">12 SPECIAL HANDLING INSTRUCTIONS</a></li></ul></li><li class="nav-item"><a href="#drop-d91389e0-c234-44d9-8327-91b121723a8f" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PART II: SCIENTIFIC INFORMATION</a><ul id="drop-d91389e0-c234-44d9-8327-91b121723a8f" class="navbar-nav small collapse"><li class="nav-item"><a href="#ee2875272-8229-4c12-919e-827854dcd76a" class="nav-link">13 PHARMACEUTICAL INFORMATION</a></li><li class="nav-item"><a href="#ab2875272-8229-4c12-919e-827854ddd76a" class="nav-link">14 CLINICAL TRIALS</a><ul class="navbar-nav"><li class="nav-item"><a href="#a2875272-8229-4c12-919e-827854ddd78a" class="nav-link">14.1 Trial Design and Study Demographics</a></li><li class="nav-item"><a href="#a2875272-8229-4a12-919e-827854ddd78a" class="nav-link">14.2 Study Results</a></li><li class="nav-item"><a href="#df2875272-8229-4c12-919e-827954ddd78a" class="nav-link">14.3 Comparative Bioavailability Studies</a></li><li class="nav-item"><a href="#bba325d26-c939-443a-901e-526ddc314522" class="nav-link">14.4 Immunogenicity</a></li><li class="nav-item"><a href="#b7a325d26-c939-443a-901e-526ddc314522" class="nav-link">14.5 Clinical Trials - Reference Biologic Drug</a></li></ul></li><li class="nav-item"><a href="#a2875272-8229-4c12-a19e-827954ddd78a" class="nav-link">15 MICROBIOLOGY</a></li><li class="nav-item"><a href="#a42a7572-8229-4c12-a19e-827954ddd78a" class="nav-link">16 NON-CLINICAL TOXICOLOGY</a><ul class="navbar-nav"><li class="nav-item"><a href="#a2875272-8229-4c12-a19e-8279549dd78a" class="nav-link">16.1 Comparative Non-Clinical Pharmacology and Toxicology</a><ul class="navbar-nav"><li class="nav-item"><a href="#a2875272-8229-4c12-a19e-8279749dd78a" class="nav-link">16.1.1 Comparative Non-Clinical Pharmacodynamics</a></li><li class="nav-item"><a href="#a2875212-8229-4c12-a19e-8279749dd78a" class="nav-link">16.1.2 Comparative Toxicology</a></li></ul></li></ul></li><li class="nav-item"><a href="#ef8a4d48-0fc3-4e44-b4b6-550140d4de5d" class="nav-link">17 SUPPORTING PRODUCT MONOGRAPHS</a></li></ul></li><li class="nav-item"><a href="#drop-be74b6e6-c461-4a5f-a18e-ed321b381456" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PATIENT MEDICATION INFORMATION</a><ul id="drop-be74b6e6-c461-4a5f-a18e-ed321b381456" class="navbar-nav small collapse"><li class="nav-item"><a href="#ea4ec98b-b2d3-4d73-877c-aaa5eb28997d" class="nav-link">READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE</a></li><li class="nav-item"><a href="#baa4d498-0gc3-4e44-bcb6-550140d4de5d" class="nav-link">What is [Brand name] used for?</a></li><li class="nav-item"><a href="#bca4d498-0gc3-4e44-bcb6-550140d4de5d" class="nav-link">How does [Brand name] work?</a></li><li class="nav-item"><a href="#bca4d498-0gc3-4e44-bcb6-55013024de5d" class="nav-link">What are the ingredients in [Brand name]?</a></li><li class="nav-item"><a href="#bca4d498-0gc3-4e54-bcb6-550130d4de5d" class="nav-link">[Brand name] comes in the following dosage forms:</a></li><li class="nav-item"><a href="#bca4c498-00c3-4e44-bcb6-550134d4de5d" class="nav-link">Do not use [Brand name] if:</a></li><li class="nav-item"><a href="#b6b37351-bbc9-46d9-b148-27ba3cb0a75e" class="nav-link">To help avoid side effects and ensure proper use, talk to your
                                healthcare professional before you take [Brand name]. Talk about any
                                health conditions or problems you may have, including if
                                you:</a></li><li class="nav-item"><a href="#edac0d6f-3c91-48b5-99c0-e0f940925d37" class="nav-link">Other warnings you should know about:</a></li><li class="nav-item"><a href="#bca4c498-0ac3-4e44-bcb6-550134d4de5d" class="nav-link">The following may interact with [Brand name]:</a></li><li class="nav-item"><a href="#e23321cd-5111-4aa3-b650-74f93bcda261" class="nav-link">How to take [Brand name]:</a></li><li class="nav-item"><a href="#cd0892a2-0e32-4fb7-9cc9-1bbfff60dee7" class="nav-link">Usual dose:</a></li><li class="nav-item"><a href="#beaaa5b8-6693-4d4c-a897-fa5c9562b1be" class="nav-link">Overdose:</a></li><li class="nav-item"><a href="#ffd59b8d-fe66-4d86-a54f-0613d4168199" class="nav-link">Missed dose:</a></li><li class="nav-item"><a href="#cb61f530-b95a-4047-b8ea-861c5a7a05e8" class="nav-link">What are possible side effects from using [Brand name]?</a></li><li class="nav-item"><a href="#c9d75711-2ce9-451e-aa51-91026ec1555e" class="nav-link">Storage:</a></li><li class="nav-item"><a href="#f6693e7a-21c9-492f-833b-4e8f3911d3a5" class="nav-link">If you want more information about [Brand name]:</a></li></ul></li></ul></div></section></div></aside><main class="col"><div class="container-fluid" id="main"><div class="row position-relative"><div class="col"><div class="card mb-2 hide-in-print" id="bdeefc11-4315-41e3-8c56-83e8bf4f770b"><h5 class="card-header text-white bg-aurora-accent1">PRODUCT DETAILS</h5><div id="product-accordion"><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="company-details"><h6 class="card-header p-0 bg-aurora-light"><button class="btn bg-aurora-light text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-company-details" aria-expanded="true" aria-controls="collapse-company-details">COMPANY DETAILS</button></h6><div id="collapse-company-details" class="collapse show spl" data-parent="#product-accordion"><table xmlns="" width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Market Authorization Holder -&nbsp;</span>Acme Pharma Inc. (1111)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>9526 Columbia St.</td></tr><tr><td>Hanover Park,&nbsp;Illinois,&nbsp;60133</td></tr><tr><td>United States of America (the)</td></tr></table></td><td class="formItem"><div>Tel: +1-202-555-0178</div><div>Email: <a href="mailto:test@canada.ca">test@canada.ca</a></div><div>Web: <a href="http://www.test.ca">http://www.test.ca</a></div></td></tr></table><table xmlns="" width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Canadian Importer/Distributor -&nbsp;</span>Acme Distributing Ltd. (0000)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>250 Lanark Ave.</td></tr><tr><td>Ottawa,&nbsp;Ontario,&nbsp;K1Z 6R5</td></tr><tr><td>Canada</td></tr></table></td><td class="formItem"><div>Tel: +1-416-555-0134</div><div>Email: <a href="mailto:test.2@canada.ca">test.2@canada.ca</a></div><div>Web: <a href="http://www.test.ca">http://www.test.ca</a></div></td></tr></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-1"><h6 class="card-header p-0 bg-aurora-light"><button class="btn bg-aurora-light text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-1" aria-expanded="true" aria-controls="collapse-product-1">Product #1 LORUM IPSUM TABLETS 
		(acetaminophen), 		
			
			ACETAMINOPHEN&nbsp;
				100&nbsp;								
			mg&nbsp;
			/ ACEXAMIC ACID&nbsp;
				45&nbsp;								
			mg&nbsp;
			Tablet</button></h6><div id="collapse-product-1" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM TABLETS&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM TABLETS</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">12345678</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Oral use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Tablet</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">100&nbsp;								
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>ACEXAMIC ACID</strong> (7IC4BO7D3R)  (ACEXAMIC ACID - 7IC4BO7D3R) </td><td class="formItem">ACEXAMIC ACID (7IC4BO7D3R) </td><td class="formItem">45&nbsp;								
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off white)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">BULLET</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">10mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">NO SCORE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A;45</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem">APPLE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 9: Fixed-Dose Combination - two or more active ingredients combined in a single dosage form</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Increased Thrombolysis [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">ABC-1234<br></td><td class="formItem">30 &nbsp;in&nbsp;1 Bottle<br></td><td class="formItem">APPROVED<br></td><td class="formItem">2017-01-02<br></td><td class="formItem">2018-01-01<br></td></tr><tr class="formTableRow"><th scope="row" class="formItem">2</th><td class="formItem">ABC-6789<br>ABC-5678<br></td><td class="formItem">4 &nbsp;in&nbsp;1 Box<br>10 &nbsp;in&nbsp;1 Blister<br></td><td class="formItem">APPROVED<br><br></td><td class="formItem">2017-01-01<br><br></td><td class="formItem"><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-2"><h6 class="card-header p-0 bg-aurora-light"><button class="btn bg-aurora-light text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-2" aria-expanded="true" aria-controls="collapse-product-2">Product #2 LORUM IPSUM CAPSULE 
		(acetaminophen), 		
			
			ACETAMINOTADALAFIL&nbsp;
				200&nbsp;								
			mg&nbsp;
			/ ACETAMINOPHEN&nbsp;
				50&nbsp;								
			mg&nbsp;
			Capsule, hard</button></h6><div id="collapse-product-2" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM CAPSULE&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen capsule, hard</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM CAPSULE</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">45612322</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Oral use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Capsule, hard</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOTADALAFIL</strong> (CTF06O4T7I)  (ACETAMINOTADALAFIL - CTF06O4T7I) </td><td class="formItem">ACETAMINOTADALAFIL (CTF06O4T7I) </td><td class="formItem">200&nbsp;								
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">50&nbsp;								
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off white),&nbsp;RED (dark red)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">DIAMOND</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">8mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">NO SCORE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">L;200</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem">APPLE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 9: Fixed-Dose Combination - two or more active ingredients combined in a single dosage form</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Lysosomal Function Alteration [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">ABC-6789<br>ABC-5678<br></td><td class="formItem">4 &nbsp;in&nbsp;1 Box<br>10 &nbsp;in&nbsp;1 Blister<br></td><td class="formItem">APPROVED<br><br></td><td class="formItem">2017-01-01<br><br></td><td class="formItem"><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-3"><h6 class="card-header p-0 bg-aurora-light"><button class="btn bg-aurora-light text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-3" aria-expanded="true" aria-controls="collapse-product-3">Product #3 LORUM IPSUM POWDER 
		(acetaminophen), 		
			
			ACETAMINOPHEN&nbsp;
				1&nbsp;								
			mg&nbsp;
			Powder for oral solution</button></h6><div id="collapse-product-3" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM POWDER&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen powder for oral solution</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM POWDER</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">65432551</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Subcutaneous use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Powder for oral solution</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">1&nbsp;								
			mg&nbsp;in&nbsp;5&nbsp;mL</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (OFF WHITE)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 0: Not a Combination Product</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Lysosomal Function Alteration [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1212<br><br><br></td><td class="formItem">1 &nbsp;in&nbsp;1 Box<br>2 &nbsp;in&nbsp;1 Bag<br>5 mL&nbsp;in&nbsp;1 Vial<br></td><td class="formItem">APPROVED<br><br><br></td><td class="formItem">2018-06-01<br><br><br></td><td class="formItem"><br><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-4"><h6 class="card-header p-0 bg-aurora-light"><button class="btn bg-aurora-light text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-4" aria-expanded="true" aria-controls="collapse-product-4">Product #4 LORUM IPSUM 
		(acetaminophen)</button></h6><div id="collapse-product-4" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">61325884</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem"></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1111<br></td><td class="formItem">1 &nbsp;in&nbsp;1 Box<br></td><td class="formItem">APPROVED<br></td><td class="formItem">2017-01-02<br></td><td class="formItem">2018-01-01<br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">APPROVED</td><td class="formItem">2017-10-09</td><td class="formItem"></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Quantity of Parts</td></tr><tr><th scope="col" class="formTitle">Part&nbsp;#</th><th scope="col" class="formTitle">Package Quantity</th><th scope="col" class="formTitle">Total Product Quantity</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>Part&nbsp;1</strong></td><td class="formItem">1 Vial </td><td class="formItem">5&nbsp;mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>Part&nbsp;2</strong></td><td class="formItem">1 Injection syringe </td><td class="formItem">5&nbsp;mL</td></tr></table></td></tr><tr><td><table width="100%" cellspacing="0" cellpadding="5"><tr><td class="contentTableTitle">Part&nbsp;1&nbsp;of&nbsp;2</td></tr><tr><td class="contentTableTitle"><strong>LORUM IPSUM POWDER&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen powder for oral solution</span></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM POWDER</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02490064</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Intravenous use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Powder for oral solution</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">50&nbsp;								
			ug&nbsp;in&nbsp;1&nbsp;mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (OFF WHITE)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 0: Not a Combination Product<br>Type 8: Kit - two or more drug products having separate DINs, or a combination of one or more drug products and non-drug products packaged for use together</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Bisphosphonate [EPC]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1212<br></td><td class="formItem">5 mg&nbsp;in&nbsp;1 Vial<br></td><td class="formItem"><br></td><td class="formItem"><br></td><td class="formItem"><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">218531</td><td class="formItem"></td><td class="formItem"></td><td class="formItem"></td></tr></table></td></tr><tr><td><table width="100%" cellspacing="0" cellpadding="5"><tr><td class="contentTableTitle">Part&nbsp;2&nbsp;of&nbsp;2</td></tr><tr><td class="contentTableTitle"><strong>WATER&nbsp;		
					</strong><br><span class="contentTableReg">sodium chloride, water for injections oral liquid</span></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">WATER</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">Sodium chloride, water for injections</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02490065</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Intravenous use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Oral liquid</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>SODIUM CHLORIDE</strong> (451W47IQ8X)  (SODIUM CHLORIDE - 451W47IQ8X) </td><td class="formItem">SODIUM CHLORIDE (451W47IQ8X) </td><td class="formItem">1&nbsp;								
			mL&nbsp;in&nbsp;1&nbsp;mL</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (Colourless to off white)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 1: Prefilled Drug Device/Delivery system (syringe, patch, etc.)</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">OTC</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Blood Pressure Alteration [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1234<br></td><td class="formItem">4 mL&nbsp;in&nbsp;1 Injection syringe<br></td><td class="formItem"><br></td><td class="formItem"><br></td><td class="formItem"><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">218531</td><td class="formItem"></td><td class="formItem"></td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-5"><h6 class="card-header p-0 bg-aurora-light"><button class="btn bg-aurora-light text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-5" aria-expanded="true" aria-controls="collapse-product-5">Product #5 LORUM IPSUM CELLS RANGE 
		(acetaminophen), 		
			
			ACETAMINOPHEN&nbsp;
				2,000,000&nbsp;-&nbsp;60,000,000&nbsp;								
			CELLS&nbsp;
			Solution for injection</button></h6><div id="collapse-product-5" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM CELLS RANGE&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen solution for injection</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM CELLS RANGE</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">12345678</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Oral use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Solution for injection</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">2,000,000&nbsp;-&nbsp;60,000,000&nbsp;								
			CELLS</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off white)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">BULLET</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">10mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">NO SCORE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A;45</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem">APPLE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 0: Not a Combination Product</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Blood Pressure Alteration [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">ABC-1234<br></td><td class="formItem">30 &nbsp;in&nbsp;1 Bottle<br></td><td class="formItem">APPROVED<br></td><td class="formItem">2017-01-02<br></td><td class="formItem">2018-01-01<br></td></tr><tr class="formTableRow"><th scope="row" class="formItem">2</th><td class="formItem">ABC-6789<br>ABC-5678<br></td><td class="formItem">4 &nbsp;in&nbsp;1 Box<br>10 &nbsp;in&nbsp;1 Blister<br></td><td class="formItem">APPROVED<br><br></td><td class="formItem">2017-01-01<br><br></td><td class="formItem"><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section></div></div><div class="card mb-2 force-page-break-after" id="eed00b53-cdb2-4aa6-9e82-88b7d793b208"><h5 class="card-header text-white bg-aurora-accent1 hide-in-print">TITLE PAGE</h5><div class="spl title-page title-page-row"><p class="First">PRODUCT MONOGRAPH</p><p>INCLUDING PATIENT MEDICATION INFORMATION</p><br><p>[Scheduling Symbol] <span class="Bold">[BRAND NAME]</span></p><p>[Proper name in final dosage form]</p><p>[Dosage Form(s), Strength(s) and Route(s) of Administration]</p><p>[Pharmaceutical Standard (if applicable)]</p><p>[Therapeutic Classification]</p><br><p>[For products that have been authorized under the Notice of Compliance with Conditions (NOC/c) policy, include the following boxed statement:]</p><table width="100%"><tbody class="Headless" align="left"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">"[Brand name], indicated for:</p><p>- [ ]</p><p>has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for &lt;Brand name&gt; please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: 
                                                    <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html">https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html"</a></p><p>[For market authorizations without conditions]</p><p>"[Brand name], indicated for:</p><p>- [ ]</p><p>has been issued market authorization without conditions."</p></td></tr></tbody></table></div><div class="spl title-page-row title-page-rule"><div class="title-page-left"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="0tp1.2" id="f187daf9-5e75-425a-9de6-f6ce1af2a965"><a name="ac26f58c-721a-4c51-8bbc-c9dddb1f1233"> </a><a name="section-2.2"> </a><p></p><h2 xmlns="">Company Name and Address</h2><p xmlns="" class="First"> Company Name<br> Street address<br> City, Province<br> Postal code<br></p></div><div xmlns="http://www.w3.org/1999/xhtml" class="Section"><br></br><h2 style="display: inline;">Submission Control Number: </h2>123456</div></div><div class="title-page-right"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="0tp1.3" id="bf2dab4e-fd04-4ec9-9cdc-247188622d0f"><a name="e5f1dea3-d907-4664-b46f-e1d9736d47af"> </a><a name="section-2.3"> </a><p></p><h2 xmlns="">Date of Initial Authorization:</h2><p xmlns="" class="First">January 1, 2018</p></div><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="0tp1.4" id="d0184119-8fd7-4378-af77-b227c39e8445"><a name="ad78301c-29a9-41af-96f8-d58815fed296"> </a><a name="section-2.4"> </a><p></p><h2 xmlns="">Date of Revision:</h2><p xmlns="" class="First">January 1, 2019</p></div></div></div><div class="spl title-page title-page-row"><p class="First">[BRAND NAME<span class="Sup">®</span> or ™] is a registered
                                    trademark of [COMPANY]</p></div></div><div class="card mb-2 pb-2" id="dd1e1c43-f0d3-4ba8-b1f5-bd009a5dd5a8"><h5 class="card-header text-white bg-aurora-accent1">NOTICE OF COMPLIANCE WITH CONDITIONS</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="0NOC" id="d7ceb5c8-7ee9-4fd2-884e-7a50c06b27e1"><a name="dd1e1c43-f0d3-4ba8-b1f5-bd009a5dd5a8"> </a><a name="section-3"> </a><p></p><h1 xmlns="">NOTICE OF COMPLIANCE WITH CONDITIONS</h1><table xmlns="" width="100%"><tbody class="Headless" align="left"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For all products authorized under the Notice of Compliance with Conditions policy, include the following information:</p><br><p><span class="Bold">What is a Notice of Compliance with Conditions (NOC/c)?</span></p><br><p><span class="Italics">An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada.</span></p><br><p><span class="Italics">Products authorized under Health Canada’s NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to this  product on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame.</span></p></td></tr></tbody></table></div></div></div><div class="card mb-2" id="dd1e1c93-f0d3-4ba8-b1f5-ad009a5dd5a8"><h5 class="card-header text-white bg-aurora-accent1">RECENT MAJOR LABEL CHANGES</h5><div class="spl recent-changes"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="1RMLC" id="d7cee5c8-7ee9-4fd2-184e-7a50c06b27e1"><a name="dd1e1c93-f0d3-4ba8-b1f5-ad009a5dd5a8"> </a><a name="section-4"> </a><p></p><h1 xmlns="">RECENT MAJOR LABEL CHANGES</h1><table xmlns="" width="100%"><tbody class="Headless" align="left"><tr class="First"><td>[Section number and heading], [Subsection number and
                                        heading]</td><td>[MM/YYYY]</td></tr><tr class="Last"><td>[Section number and heading], [Subsection number and
                                        heading]</td><td>[MM/YYYY]</td></tr></tbody></table></div></div></div><div class="card mb-2 pb-2" id="dd1e1c41-f0d3-4ba8-b1f5-bd009a5dd5a8"><h5 class="card-header text-white bg-aurora-accent1">BIOSIMILAR BIOLOGIC DRUG</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="0BBD" id="d7ceb5c1-7ee9-4fd2-884e-7a50c06b27e1"><a name="dd1e1c41-f0d3-4ba8-b1f5-bd009a5dd5a8"> </a><a name="section-5"> </a><p></p><h1 xmlns="">BIOSIMILAR BIOLOGIC DRUG</h1><table xmlns="" width="100%"><tbody class="Headless" align="left"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For biosimilar biologic drugs (hereafter referred to as biosimilars), include the following statement:</p><br><p><span class="Italics">[Biosimilar brand name (proper name)] is a biosimilar biologic drug (biosimilar) to [Reference biologic drug brand name].</span></p></td></tr></tbody></table></div></div></div><div class="card mb-2 pb-2" id="e6bb83b9-2602-4f96-9077-b8b9535c254e"><h5 class="card-header text-white bg-aurora-accent1">PART I: HEALTH PROFESSIONAL INFORMATION</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="pi00" id="d6a947eb-e2be-45c0-8b2e-15d0d0eebea8"><a name="e6bb83b9-2602-4f96-9077-b8b9535c254e"> </a><a name="section-6"> </a><p></p><h1 xmlns="">PART I: HEALTH PROFESSIONAL INFORMATION</h1><div class="Section" data-sectionCode="pi01" id="c2ea4fad-2b79-4dbc-8d99-6843adc2dec8"><a name="aa3f869a-7734-425a-85d8-b8bd4d3500a5"> </a><a name="section-6.1"> </a><p></p><h2 xmlns="">1 INDICATIONS</h2><p xmlns="" class="First">[BRAND NAME] (proper name in final dosage form) is indicated for:</p><ul xmlns=""><li>[text]</li><li>[text]</li></ul><p xmlns="">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For biosimilars, the wording of each indication authorized for the biosimilar should be identical to the reference biologic drug product monograph, and the following statement should be made: </p><br><p><span class="Italics">Indications have been granted on the basis of similarity between [Biosimilar brand name] and the reference biologic drug [Reference biologic drug brand name].</span></p><br><p>For NOC/c indications: include a brief statement regarding the uncertainties and/or limitations of the indications.</p></td></tr></tbody></table><div class="Section" data-sectionCode="pi01.1" id="f2aa7e0e-2042-4a4c-a783-9ad4e8717a32"><a name="b9db4ce0-3f46-434a-bd7b-4a3e010adaad"> </a><a name="section-6.1.1"> </a><p></p><h3 xmlns="">1.1 Pediatrics</h3><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">One of the following or similar statements should be used:</p><br><p><span class="Italics">Pediatrics (age range): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of [Brand name] in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use. [Include cross-reference to relevant sections.]</span></p><br><p>or</p><br><p><span class="Italics">Pediatrics (age range): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.</span></p><br><p>or</p><br><p><span class="Italics">Pediatrics (age range): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of [Brand name] in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. [Include cross-reference to relevant sections.]</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi01.2" id="be75cfb9-3132-4903-800b-267427388a13"><a name="b9db4be0-3f46-43fa-bd7b-4a3e010adaad"> </a><a name="section-6.1.2"> </a><p></p><h3 xmlns="">1.2 Geriatrics</h3><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">One of the following or similar statements may be used:</p><br><p><span class="Italics">Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.</span></p><br><p>or</p><br><p><span class="Italics">Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness.</span></p></td></tr></tbody></table></div></div><div class="Section" data-sectionCode="pi02" id="be75cfb9-3131-4903-800b-367427388a13"><a name="b90b4be0-3f46-437a-bd7b-4a3e010adaad"> </a><a name="section-6.2"> </a><p></p><h2 xmlns="">2 CONTRAINDICATIONS</h2><ul xmlns=""><li>[text]</li></ul><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Describe absolute contraindications, meaning those situations in which the drug should not be used because the risk outweighs any potential therapeutic benefit. For example: </p><br><p><span class="Italics">[Proper name] is contraindicated with co-administration of [Drug X] as it may result in increased concentrations of [Drug X] due to inhibition of CYP3A, which may lead to QT interval prolongation and torsades de pointes. See 7 WARNINGS AND PRECAUTIONS and 9 DRUG INTERACTIONS.</span></p><br><p>For hypersensitivity reactions, the following or similar statement should be used: </p><br><p><span class="Italics">[Proper name] is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi03" id="be75cfb9-3131-4903-800b-267427398a13"><a name="b9fb4be0-3f46-437a-bd7b-4a3e010adaad"> </a><a name="section-6.3"> </a><p></p><h2 xmlns="">3 SERIOUS WARNINGS AND PRECAUTIONS BOX</h2><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" frame="border" width="100%"><tbody class="Headless"><tr class="First"><td align="center"><span class="Bold">Serious Warnings and
                                                  Precautions</span></td></tr><tr class="Last"><td><ul><li>[text]</li><li>[text]</li></ul></td></tr></tbody></table><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Clinically significant or serious (e.g., life-threatening) safety hazards should be placed in this box, with a cross reference to the relevant section(s) for more detailed information. Generally, this text should not exceed 20 lines.</p><br><p>For all radiopharmaceuticals the Serious Warnings and Precautions Box should contain the following or similar statement:</p><br><p><span class="Italics">Radiopharmaceuticals should be used only by those health professionals who are appropriately qualified in the use of radioactive prescribed substances in or on humans.</span></p><br><p>In the absence of a serious warning or precaution identified at the time of authorization, this box is omitted, along with the heading 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi04" id="be75cfb9-3131-4903-800b-267727398a13"><a name="b9db4be0-3f46-434a-bd7b-4a3e010adaad"> </a><a name="section-6.4"> </a><p></p><h2 xmlns="">4 DOSAGE AND ADMINISTRATION</h2><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Biosimilar specific properties should be considered, such as potentially allergenic product container materials or differences in product presentation that require biosimilar-specific storage and administration directions.</p></td></tr></tbody></table><div class="Section" data-sectionCode="pi04.1" id="be75cfb9-3131-4103-800b-267727398a13"><a name="b9db4be0-3f46-437a-bd7b-4a3e310adaad"> </a><a name="section-6.4.1"> </a><p></p><h3 xmlns="">4.1 Dosing Considerations</h3><ul xmlns=""><li>[text]</li></ul><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Briefly list all safety issues to consider that may affect dosing of the drug (e.g., renal or hepatic disease, concomitant therapy, changing from intravenous to oral therapy, lab values prior to infusion, rule out pregnancy prior to administration, pre-medication is required, duration of effect, imaging time post-injection).</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi04.2" id="b3d876c1-c36c-4ed5-8993-c507e3ab9f2e"><a name="da2d22a3-b5c2-4a62-b138-9594dd0491bb"> </a><a name="section-6.4.2"> </a><p></p><h3 xmlns="">4.2 Recommended Dose and Dosage Adjustment</h3><ul xmlns=""><li>[text]</li></ul><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Include detailed dosage information for each indication, route of administration and/or dosage form, dosage schedules, booster doses, initial dose, titration of dose, dosage range, maximum daily dose, maintenance dosage, duration of treatment and drug discontinuance, considerations for special populations. </p><br><p>In the absence of a Health Canada authorized pediatric indication, the following or similar statement should be used, with a cross-reference to relevant sections, if applicable:</p><br><p><span class="Italics">Health Canada has not authorized an indication for pediatric use. </span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi04.3" id="a63c33a5-e08a-472c-b8a2-a12dba105f4a"><a name="a473c162-e176-44d0-b797-2b7b6cf0ae43"> </a><a name="section-6.4.3"> </a><p></p><h3 xmlns="">4.3 Reconstitution</h3><p xmlns="" class="First"><span class="Bold">Oral Solutions: </span></p><ul xmlns=""><li>[text and/or table]</li></ul><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">List all recommended diluents for reconstitution. Directions should include the volume and type of diluents to be added and the approximate volume and concentration of the resulting product.</p><br><p>Recommended storage period and conditions should be stated and include cross-reference to 11 STORAGE, STABILITY AND DISPOSAL.</p></td></tr></tbody></table><p xmlns=""><span class="Bold">Parenteral Products: </span></p><ul xmlns=""><li>[table and text]</li></ul><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For intravenous use, information should be separately described for direct intravenous injection, intermittent infusion, and continuous infusion; use of in-line filters etc. </p><br><p>Include any specific precautions, storage periods and incompatibilities, and include cross-reference to 11 STORAGE, STABILITY AND DISPOSAL.</p></td></tr></tbody></table><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><caption><span>Table - Reconstitution</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Vial Size</th><th class="Botrule Lrule Rrule Toprule">Volume of Diluent to be Added to Vial</th><th class="Botrule Lrule Rrule Toprule">Approximate Available Volume</th><th class="Botrule Lrule Rrule Toprule">Concentration per mL</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td></tr></tbody></table></div><div class="Section" data-sectionCode="pi04.4" id="a63c33a5-e08a-472c-b8a2-a12dba105f3a"><a name="a473c162-f176-44d0-b797-2b7b6cf00e43"> </a><a name="section-6.4.4"> </a><p></p><h3 xmlns="">4.4 Administration</h3><p xmlns="" class="First">[text and/or table]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Include details concerning methods of administration. Specify any special considerations (e.g., do not crush, do not split if not scored, capsule contents can be sprinkled).</p><br><p>For radiopharmaceuticals, if applicable, include the following or similar statement:</p><br><p><span class="Italics">The patient dose should be measured by a suitable radioactivity calibration system prior to administration.</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi04.5" id="a63c33a5-e08a-472c-b8a2-a12dba105f5a"><a name="a473c162-e176-44d0-b797-2b7b6cf00e33"> </a><a name="section-6.4.5"> </a><p></p><h3 xmlns="">4.5 Missed Dose</h3><p xmlns="" class="First">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Include actions to be taken in the event that a patient misses a dose.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi04.6" id="a63c98a5-e08a-472c-b8a2-a12dba105a5a"><a name="a473c162-e176-44d0-b797-2b2b6cf00e33"> </a><a name="section-6.4.6"> </a><p></p><h3 xmlns="">4.6 Image Acquisition and Interpretation</h3><p xmlns="" class="First">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For radiopharmaceuticals only, otherwise delete this subheading. Include specific requirements for image acquisition and interpretation such as type of equipment and calibration scanning or imaging time post injection, location of views, and frequency of images. </p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi04.7" id="a63c98a5-e08a-472c-b8a2-a12dba105f5a"><a name="a473c162-e176-44d0-b797-212b6cf00e33"> </a><a name="section-6.4.7"> </a><p></p><h3 xmlns="">4.7 Instructions for Preparation and Use</h3><p xmlns="" class="First">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For radiopharmaceuticals only, otherwise delete this subheading. The following or similar statement should be included:</p><br><p><span class="Italics">The components of the reagent vial are sterile and nonpyrogenic. It is essential that the user follows the directions carefully and adheres to strict aseptic technique.</span></p><br><p>or</p><br><p><span class="Italics">Use aseptic technique and wear waterproof gloves throughout the entire preparation procedure.</span></p><br><p>or</p><br><p><span class="Italics">Make all transfers of radioactive solutions with an adequately shielded syringe and maintain adequate shielding around the vial during the useful life of the radioactive product.</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi04.8" id="a63c08a5-e08a-472c-b8a2-a12dba105f5a"><a name="a173c162-e176-44d0-b797-212b6cf00e33"> </a><a name="section-6.4.8"> </a><p></p><h3 xmlns="">4.8 Radiation Dosimetry</h3><p xmlns="" class="First">[For radiopharmaceuticals only, otherwise delete this subheading. This is an example of acceptable presentation of Dose Estimate Data:]</p><p xmlns="">Final Dose Estimates: [The model and method of calculation should be specified.]</p><a xmlns="" name="t5"></a><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">ORGAN</th><th class="Botrule Lrule Rrule Toprule">mGy/MBq</th><th class="Botrule Lrule Rrule Toprule">rad/mCi</th></tr><tr><td class="Botrule Lrule Rrule Toprule">Adrenals</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Brain</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Breasts</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Gallbladder Wall</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">LLI Wall</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Small Intestine</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Stomach</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">ULI Wall</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Heart Wall</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Kidneys</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Liver</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Lungs</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Muscle</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Ovaries</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Pancreas</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Red Marrow</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Bone Surfaces</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Skin</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Spleen</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Testes</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Thymus</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Thyroid</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Urinary Bladder</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">Uterus</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr></tbody></table><p xmlns="">Effective Dose Equivalent (mSv/MBq) (rem/mCi)</p><p xmlns="">Effective Dose (mSv/MBq) (rem/mCi)</p></div></div><div class="Section" data-sectionCode="pi05" id="a63c33a5-e08a-472c-b8a2-a12dba105f6a"><a name="a473c162-e176-44d0-b797-2b7b6cf20e43"> </a><a name="section-6.5"> </a><p></p><h2 xmlns="">5 OVERDOSAGE</h2><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Include the following information:</p><br><ul><li>a description of the acute and/or long-term signs and symptoms of overdose, </li><li>potential sequelae/complications which may occur with the drug e.g. organ toxicity,</li><li>current recommended management of overdosage (e.g., monitoring, use of agonist/antagonist/antidotes, method to increase elimination and/or other clinical interventions), and</li><li>procedures that, by experience with this or similar type drugs, are known or reasonably expected to be unnecessary or unsuitable (e.g., those that may be hazardous to the patient).</li></ul></td></tr></tbody></table><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For management of a suspected drug overdose, contact your regional poison control centre.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi06" id="a63c33a5-e08a-472c-b8a2-a12dba105f7a"><a name="a471c162-e176-44d0-b797-2b7b6cf00e43"> </a><a name="section-6.6"> </a><p></p><h2 xmlns="">6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</h2><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">To help ensure the traceability of biologic products, including biosimilars, health professionals should recognise the importance of recording both the brand name and the non-proprietary (active ingredient) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.</p><br><p>To help ensure the traceability of vaccines for patient immunization record-keeping as well as safety monitoring, health professionals should record the time and date of administration, quantity of administered dose (if applicable), anatomical site and route of administration, brand name and generic name of the vaccine, the product lot number and expiry date.</p></td></tr></tbody></table><a xmlns="" name="t6"></a><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><caption><span>Table - Dosage Forms, Strengths, Composition and Packaging</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Route of Administration </th><th class="Botrule Lrule Rrule Toprule">Dosage Form / Strength/Composition </th><th class="Botrule Lrule Rrule Toprule">Non-medicinal Ingredients</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[oral]</td><td class="Botrule Lrule Rrule Toprule">[tablet 5 mg, 10 mg]</td><td class="Botrule Lrule Rrule Toprule">[List all non-medicinal ingredients in alphabetical
                                                order.]</td></tr></tbody></table><p xmlns="" class="First">[text]</p><p xmlns=""><span class="Bold">Description</span></p><p xmlns="">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For biosimilars only, otherwise delete this subheading. Include a narrative description of the biosimilar biologic drug that is similar to the narrative in the reference biologic drug monograph. Incorporate changes as necessary where there are descriptive differences between the biosimilar and the reference biologic drug due to, for example, differences in formulation.</p></td></tr></tbody></table><div class="Section" data-sectionCode="pi06.1" id="a63c98a5-e08a-400c-b8a2-a12dba105f5a"><a name="a473c162-e176-44d0-b797-212b60000e33"> </a><a name="section-6.6.1"> </a><p></p><h3 xmlns="">6.1 Physical Characteristics</h3><p xmlns="" class="First">[table]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">For radiopharmaceuticals only, otherwise delete this subheading.  Include physical half-life, principle radiation emission data, physical decay chart (tabular format), parent and daughter radionuclides data.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi06.2" id="a63c90a5-e08a-400c-b8a2-a12dba105f5a"><a name="a473c162-e176-44d0-b797-214b60000e33"> </a><a name="section-6.6.2"> </a><p></p><h3 xmlns="">6.2 External Radiation</h3><p xmlns="" class="First">[table]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">For radiopharmaceuticals only, otherwise delete this subheading. Include specific gamma ray constant for the radioisotope, radiation attenuation by lead shielding (tabular format), parent and daughter radionuclides data.</p></td></tr></tbody></table></div></div><div class="Section" data-sectionCode="pi07" id="a63c33a5-e08a-472c-b8a2-a12dba115f7a"><a name="a4731162-e176-44d0-b797-2b7b6cf00e43"> </a><a name="section-6.7"> </a><p></p><h2 xmlns="">7 WARNINGS AND PRECAUTIONS</h2><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">If applicable, include one of the following statements:</p><br><p><span class="Italics">Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.</span></p><br><p>For blood products: </p><br><p><span class="Italics">This product is prepared from large pools of human plasma. Thus, there is a possibility it may contain causative agents of viral or other undetermined diseases.</span></p><br><p>For all radiopharmaceuticals:</p><br><p><span class="Italics">The product should be administered under the supervision of a health professional who is experienced in the use of radiopharmaceuticals. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available.</span></p><br><p><span class="Italics">The radiopharmaceutical product may be received, used and administered only by authorized persons in designated clinical settings. Its receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licenses of local competent official organizations.</span></p><br><p><span class="Italics">As in the use of any other radioactive material, care should be taken to minimize radiation exposure to patients consistent with proper patient management, and to minimize radiation exposure to occupational workers.</span></p></td></tr></tbody></table><p xmlns="" class="First">[Subheadings to be included as applicable, in alphabetical order:]</p><p xmlns=""><span class="Bold">General</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include information that does not fall under the subheadings listed below.</p><br><p>For products derived from plasma, explain the inherent risks when products have been derived from plasma.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Carcinogenesis and Mutagenesis</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include only human data where there is evidence that the drug is carcinogenic or mutagenic. Where there is only animal data, a cross-reference to the animal data in 16 NON-CLINICAL TOXICOLOGY should be provided.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Cardiovascular</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Includes QTc prolongation (cross reference to 10.2 Pharmacodynamics as required.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Contamination</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">For radiopharmaceuticals, include practical information for the patient to minimize the contamination potential after receiving the drug. This information must also appear in the Patient Medication Information.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Dependence/Tolerance</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include effects for both physical and psychological dependence. Treatment of the effects of the dependence should be provided.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Driving and Operating Machinery</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">If applicable, this subheading should include the following or similar statement:</p><br><p><span class="Italics">Exercise caution when driving or operating a vehicle or potentially dangerous machinery.</span></p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Ear/Nose/Throat</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Endocrine and Metabolism</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">This subheading should specify genetic polymorphism where applicable.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Gastrointestinal</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Genitourinary</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Hematologic</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Hepatic/Biliary/Pancreatic</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">When possible, idiopathic versus metabolic liver failure should be described.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Immune</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Monitoring and Laboratory Tests</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Musculoskeletal</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Neurologic</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Ophthalmologic</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Peri-Operative Considerations</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include information on management before, during and after surgery.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Psychiatric</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Behavioural changes, or potential (e.g., suicidal ideation) should be stated.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Renal</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Reproductive Health: Female and Male Potential</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Cross-reference to other relevant sections (e.g. 2 CONTRAINDICATIONS, 7.1.1 Pregnant Women); consider contraception for both females and males.</p></td></tr></tbody></table><ul xmlns=""><li><span class="Bold">Fertility</span></li></ul><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include a summary of relevant information of effects of the drug on fertility from animal or human exposure. In the absence of information, clearly state that no data exist.</p></td></tr></tbody></table><p xmlns="">[text]</p><ul xmlns=""><li><span class="Bold">Function</span></li></ul><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include effects on sexual desire, erection, orgasm and ejaculation.</p></td></tr></tbody></table><p xmlns="">[text]</p><ul xmlns=""><li><span class="Bold">Teratogenic Risk</span></li></ul><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Teratogenic and nonteratogenic effects on the fetus should be included. If contraindicated in pregnancy, this should be stated in 2 CONTRAINDICATIONS.</p></td></tr></tbody></table><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Respiratory</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Sensitivity/Resistance</span></p><p xmlns="">[text]</p><p xmlns=""><span class="Bold">Skin</span></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include information on local reactions to vaccination, human photosensitivity where applicable, etc.</p></td></tr></tbody></table><p xmlns="">[text]</p><div class="Section" data-sectionCode="pi07.1" id="a63c33a5-e08a-472c-b8a2-a12dbc115f7a"><a name="a473c162-e176-44d0-bb97-2b7b6cf00e43"> </a><a name="section-6.7.1"> </a><p></p><h3 xmlns="">7.1 Special Populations</h3><div class="Section" data-sectionCode="pi07.1.1" id="a63c33a5-e08a-472c-b8a2-b12dbc115f7a"><a name="a473c162-e176-4ad0-b797-2b7b6cf00e43"> </a><a name="section-6.7.1.1"> </a><p></p><h4 xmlns="">7.1.1 Pregnant Women</h4><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include information related to Pregnancy Registries. The availability of a pregnancy exposure registry should also be included in the Patient Medication Information. If information on birth defects and miscarriage is available for the patient population for whom the drug is labelled, it must also be included, along with the following, when available:</p><br><ul><li>Disease-associated maternal and/or fetal risk</li><li>Maternal adverse reactions</li><li>Embryo/Fetal/Neonatal adverse reactions</li><li>Labour and/or delivery</li></ul><p>The extent of exposure in pregnancy during clinical trials should be included:</p><br><p>Wide: &gt; 1,000 pregnancies<br>Limited: &lt; 1,000 pregnancies<br>Very Limited: individual cases only<br>No experience.</p><br><p>For radiopharmaceuticals the following or similar statement may be included:</p><br><p><span class="Italics">Ideally, examinations using radiopharmaceuticals, especially those elective in nature of women of childbearing capability, should be performed during the first ten days following the onset of menses, or after ensuring the woman is not pregnant. The benefit of using a diagnostic radiopharmaceutical should be weighed against the possible risk to an embryo or a fetus.</span></p></td></tr></tbody></table><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi07.1.2" id="a63c33a5-e08a-472c-b8a2-b12dbd115f7a"><a name="a473c162-1176-44d0-b797-2b7b6cf00e43"> </a><a name="section-6.7.1.2"> </a><p></p><h4 xmlns="">7.1.2 Breast-feeding</h4><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">If studies have shown that the drug is not excreted in human breast milk, it should be stated. In the absence of human data, pertinent animal data should be included along with the following or similar statement:</p><br><p><span class="Italics">It is unknown if [Brand name] [product] is excreted in human milk. Precaution should be exercised because many drugs can be excreted in human milk.</span></p><br><p>For radiopharmaceuticals, the following or similar statement should be included:</p><br><p><span class="Italics">Where an assessment of the risk to benefit ratio suggests the use of this product in nursing mothers, formula feeding should be substituted for breast feeding.</span></p></td></tr></tbody></table><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi07.1.3" id="a63c33a5-e08a-472c-b8c2-b12dbc115f7a"><a name="a473c162-e176-44d0-b787-2b7b6cf00e43"> </a><a name="section-6.7.1.3"> </a><p></p><h4 xmlns="">7.1.3 Pediatrics</h4><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">In the absence of a Health Canada authorized pediatric indication, the following statement should be used:</p><br><p><span class="Italics"><span class="Bold">Pediatrics (age range):</span> No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.</span></p><br><p>or</p><br><p><span class="Italics"><span class="Bold">Pediatrics (age range):</span> Based on the data submitted and reviewed by Health Canada, the safety and efficacy of [Brand name] in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. [Include cross-reference to relevant sections.]</span></p></td></tr></tbody></table><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi07.1.4" id="a63c33a5-e08a-472c-b8d2-b12dbc115f7a"><a name="a473c162-e176-44d0-b797-2b7b6df00e43"> </a><a name="section-6.7.1.4"> </a><p></p><h4 xmlns="">7.1.4 Geriatrics</h4><p xmlns="" class="First">[text]</p></div></div></div><div class="Section" data-sectionCode="pi08" id="a63c33a5-e08a-472c-b8a2-b22dbc115f7a"><a name="a473c162-e176-44d0-b797-2b7b6cf11e43"> </a><a name="section-6.8"> </a><p></p><h2 xmlns="">8 ADVERSE REACTIONS</h2><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For biosimilars, include the following or similar statement:</p><br><p><span class="Italics">The adverse drug reaction profiles reported in clinical studies that compared [Biosimilar brand name] to the reference biologic drug were comparable. The description of adverse reactions in this section is based on clinical experience with the reference biologic drug.</span></p></td></tr></tbody></table><div class="Section" data-sectionCode="pi08.1" id="a63c33a5-e08a-472c-b8a2-b12dbd215f7a"><a name="a473c162-e176-44d0-b797-2b7b6cf12e43"> </a><a name="section-6.8.1"> </a><p></p><h3 xmlns="">8.1 Adverse Reaction Overview</h3><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Provide information on the most serious and/or most frequently occurring adverse reactions, or those where there have been reports of particularly severe cases. Frequencies to be stated as accurately as possible. It should not be a summary of the safety database.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi08.2" id="a63c33a5-e08a-473c-b8a2-b12dbd215f7a"><a name="a473c162-e176-44d0-b797-2b7b6cab0e43"> </a><a name="section-6.8.2"> </a><p></p><h3 xmlns="">8.2 Clinical Trial Adverse Reactions</h3><p xmlns="" class="First">Clinical trials are conducted under very specific conditions.  The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.</p><p xmlns="">[Include a brief description of data sources.]</p><p xmlns="">[text]</p><a xmlns="" name="t10"></a><table xmlns="" width="100%" style="border: solid thin; border-color: #CCCCCC;" border="1" rules="all" frame="border"><caption><span>Table [#] [Title of Table]</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule"></th><th class="Botrule Lrule Rrule Toprule">[drug name] n = [#] (%)</th><th class="Botrule Lrule Rrule Toprule">[placebo] n = [#] (%)</th></tr><tr><td class="Botrule Lrule Rrule Toprule">[use MedDRA terms for headings, as applicable]<br><span class="Bold">Cardiovascular</span><br>[text]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule"><span class="Bold">Gastrointestinal</span><br>[text]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr></tbody></table><p xmlns="">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">A brief narrative should follow the table to explain or supplement the information provided in the table where applicable. Separate tables may be required for different indications (e.g., oncology and a non-oncology indication) or different formulations (e.g., oral, intravenous) or different drug combinations.</p><br><p>Adverse reactions may also be related to genetically determined product metabolism. Subjects or patients deficient in the specific enzyme may experience a different rate or severity of adverse reactions. This should be mentioned where relevant, and correlated with data from clinical trials.</p></td></tr></tbody></table><div class="Section" data-sectionCode="pi08.2.1" id="a63c33a5-e08a-473c-b8a2-b12d0d215f7a"><a name="a473c162-e196-44d0-b797-207b6cf12e43"> </a><a name="section-6.8.2.1"> </a><p></p><h4 xmlns="">8.2.1 Clinical Trial Adverse Reactions - Pediatrics</h4><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">From pediatric studies include: age characteristics, any clinically relevant differences (i.e., seriousness or reversibility of adverse reaction) between safety profiles in adult and pediatric populations, or any relevant age groups, uncertainties due to limited experience. If the observed safety profile is consistent in children and adults this could be stated.</p></td></tr></tbody></table></div></div><div class="Section" data-sectionCode="pi08.3" id="a63c33a5-e08a-473c-b8a2-b12dbd315f7a"><a name="a473c162-e146-44d0-b797-2b7b6cf00e43"> </a><a name="section-6.8.3"> </a><p></p><h3 xmlns="">8.3 Less Common Clinical Trial Adverse Reactions</h3><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Present as a list, categorized by System Organ Class, alphabetically: e.g.,</p><p>Cardiovascular: [text]</p><p>Gastrointestinal: [text]</p></td></tr></tbody></table><div class="Section" data-sectionCode="pi08.3.1" id="a63c33a5-e08a-465c-b8a2-b12d0d215f7a"><a name="a473c162-e196-44d0-b797-20700cf12e43"> </a><a name="section-6.8.3.1"> </a><p></p><h4 xmlns="">8.3.1 Less Common Clinical Trial Adverse Reactions - Pediatrics</h4><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Present as a list, categorized by System Organ Class, alphabetically: e.g.,</p><p>Cardiovascular: [text]</p><p>Gastrointestinal: [text]</p></td></tr></tbody></table></div></div><div class="Section" data-sectionCode="pi08.4" id="a63c33a5-e08a-473c-b8a2-b22dbd215f7a"><a name="a473c162-e176-44d0-be97-2b7b6cf00e43"> </a><a name="section-6.8.4"> </a><p></p><h3 xmlns="">8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data</h3><p xmlns="" class="First"><span class="Bold">Clinical Trial Findings</span></p><p xmlns="">[table]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Outline any differences between adults, geriatrics and pediatrics as necessary with regard to abnormal laboratory findings.</p></td></tr></tbody></table><p xmlns=""><span class="Bold">Post-Market Findings</span></p><p xmlns="">[table]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Outline any differences between adults, geriatrics and pediatrics as necessary with regard to post-market abnormal laboratory findings.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi08.5" id="a63c33a5-e08a-473c-b8a2-b32dbd215f7a"><a name="a473c162-e176-44c0-b797-2b7b6cf00e43"> </a><a name="section-6.8.5"> </a><p></p><h3 xmlns="">8.5 Post-Market Adverse Reactions</h3><p xmlns="" class="First">[text and/or table]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include Canadian and international post-market adverse reactions including serious and/or unexpected adverse reactions that are reported through post-market surveillance and/or identified in Phase IV clinical trials. Adverse reactions already listed in the Clinical Trial Adverse Reactions section should not be repeated in this section unless there are changes in severity, frequency or character.</p></td></tr></tbody></table></div></div><div class="Section" data-sectionCode="pi09" id="a63c33a5-e08a-483c-b8a2-b22dbd215f7a"><a name="a473c762-e176-44d0-b797-2b7b6cf00e43"> </a><a name="section-6.9"> </a><p></p><h2 xmlns="">9 DRUG INTERACTIONS</h2><div class="Section" data-sectionCode="pi09.1" id="be75cfb9-3131-4903-800b-267527398a13"><a name="b9db4be0-3f46-437a-bd7b-4a3e01fadaad"> </a><a name="section-6.9.1"> </a><p></p><h3 xmlns="">9.1 Serious Drug Interactions</h3><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" frame="border" width="100%"><tbody class="Headless"><tr class="First"><td align="center"><span class="Bold">Serious Drug
                                                  Interactions</span></td></tr><tr class="Last"><td><p class="First">[Serious (e.g., life-threatening) drug interactions should be highlighted in this box, with a cross-reference to detailed information in 9.4 Drug-Drug Interactions.  Not to exceed 20 lines.]</p><ul><li>[text]</li><li>[text]</li></ul></td></tr></tbody></table><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">If there are no serious drug interactions at the time of authorization, this box is omitted, along with the heading 9.1 Serious Drug Interactions.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi09.2" id="a63c33a5-e08a-473c-b8a2-b14dbd315f7a"><a name="a473c162-e176-44d0-b797-2b7b6cf0de43"> </a><a name="section-6.9.2"> </a><p></p><h3 xmlns="">9.2 Drug Interactions Overview</h3><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi09.3" id="a63c33a5-e08a-473c-b8d2-b14dbd315f7a"><a name="a473c162-e176-44d0-b497-2b7b6cf00e43"> </a><a name="section-6.9.3"> </a><p></p><h3 xmlns="">9.3 Drug-Behavioural Interactions</h3><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Briefly present potential interactions in terms of individual behavioural risks including, but not limited to, alcohol consumption, sexual activity, and smoking, which may result in unfavourable adverse events or treatment outcomes.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi09.4" id="a63c33a5-e0aa-473c-b8a2-b14dbd315f7a"><a name="a273c162-e176-44d0-b797-2b7b6cf00e43"> </a><a name="section-6.9.4"> </a><p></p><h3 xmlns="">9.4 Drug-Drug Interactions</h3><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">The following or similar statement should precede the table: </p><br><p><span class="Italics">The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).</span></p><br><p>Where no interaction data is known the following or similar statement should be included:</p><br><p><span class="Italics">Interactions with other drugs have not been established.</span></p></td></tr></tbody></table><a xmlns="" name="t9.4"></a><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" rules="all" frame="border" width="100%"><caption><span>Table [#] - Established or Potential Drug-Drug
                                                Interactions</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Proper /Common name</th><th class="Botrule Lrule Rrule Toprule">Source of Evidence</th><th class="Botrule Lrule Rrule Toprule">Effect</th><th class="Botrule Lrule Rrule Toprule">Clinical comment</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[drug A]</td><td class="Botrule Lrule Rrule Toprule">[level/source of evidence, see legend]]</td><td class="Botrule Lrule Rrule Toprule">[drug A] conc</td><td class="Botrule Lrule Rrule Toprule">[Caution is warranted and therapeutic
                                                        concentration monitoring is recommended]</td></tr></tbody></table><p xmlns="" class="First">Legend: C = Case Study; CT = Clinical Trial; T =
                                            Theoretical</p></div><div class="Section" data-sectionCode="pi09.5" id="a63c33a5-e08a-47bc-b8d2-b14dbd315f7a"><a name="a473c162-e176-44d0-b997-2b7b6cf00e43"> </a><a name="section-6.9.5"> </a><p></p><h3 xmlns="">9.5 Drug-Food Interactions</h3><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Briefly present known or potential interactions with food or beverages (e.g., grapefruit, caffeine). Cross-referencing to 4 DOSAGE AND ADMINISTRATION may be required when the timing of food consumption should be considered.</p><br><p>Where no interaction data is known, the following or similar statement should be included:</p><br><p><span class="Italics">Interactions with food have not been established.</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi09.6" id="be78cfb9-3131-4903-800b-267527398a13"><a name="b9db4be0-3f46-437a-bd7b-4a3e01aadaad"> </a><a name="section-6.9.6"> </a><p></p><h3 xmlns="">9.6 Drug-Herb Interactions</h3><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Briefly present known or potential interactions with herbal products and practical guidance for the health professional.</p><br><p>Where no interaction data is known, the following or similar statement should be included:</p><br><p><span class="Italics">Interactions with herbal products have not been established.</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi09.7" id="a63c33a5-e0aa-473c-b8a2-b14dcd315f7a"><a name="a473c162-e176-44e0-b797-2b7b6cf00e43"> </a><a name="section-6.9.7"> </a><p></p><h3 xmlns="">9.7 Drug-Laboratory Test Interactions</h3><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Briefly present laboratory tests affected by the presence of the drug, such as interfering with the accuracy of the test results or methods (e.g., antihistamines diminish the positive reactions to dermal reactivity indicators).</p><br><p>Where no interaction data is known, the following or similar statement should be included:</p><br><p><span class="Italics">Interactions with laboratory tests have not been established.</span></p></td></tr></tbody></table></div></div><div class="Section" data-sectionCode="pi10" id="fa324c26-b939-4c3a-901d-516ccc314522"><a name="dc0d2dd9-1c53-49dc-bad3-d6b420d064e9"> </a><a name="section-6.10"> </a><p></p><h2 xmlns="">10 CLINICAL PHARMACOLOGY</h2><div class="Section" data-sectionCode="pi10.1" id="f7a324c26-b939-4c3a-901e-516ccc314522"><a name="ac0d2dd9-1c53-49dc-bad3-d6b420d064e9"> </a><a name="section-6.10.1"> </a><p></p><h3 xmlns="">10.1 Mechanism of Action</h3><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi10.2" id="da324c26-b939-4d3a-901e-516ccc314522"><a name="cc0d2dd9-1c53-49dc-bad3-d6b420dc64e9"> </a><a name="section-6.10.2"> </a><p></p><h3 xmlns="">10.2 Pharmacodynamics</h3><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pi10.3" id="aaa324c26-b939-4d4a-901e-516ccc314522"><a name="cc0d2dd9-1c53-49dc-bad3-d6b320d064e9"> </a><a name="section-6.10.3"> </a><p></p><h3 xmlns="">10.3 Pharmacokinetics</h3><table xmlns="" width="100%" style="border: solid thin; border-color: #CCCCCC;" rules="all" frame="border"><caption><span>Table [#] - Summary of [proper name]
                                                Pharmacokinetic Parameters in [specific patient
                                                population]</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule"></th><th class="Botrule Lrule Rrule Toprule">C<span class="Sub">max</span></th><th class="Botrule Lrule Rrule Toprule">T<span class="Sub">max</span></th><th class="Botrule Lrule Rrule Toprule">t<span class="Sub">1/2</span> (h)</th><th class="Botrule Lrule Rrule Toprule">AUC<span class="Sub">0-∞</span></th><th class="Botrule Lrule Rrule Toprule">CL</th><th class="Botrule Lrule Rrule Toprule">Vd</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">Single dose mean</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr></tbody></table><p xmlns="" class="First"><span class="Bold">Absorption:</span><br><br>[text]<br><br><span class="Bold">Distribution:</span><br><br>[text]<br><br><span class="Bold">Metabolism:</span><br><br>[text]<br><br><span class="Bold">Elimination:</span><br><br>[text]<br><br><span class="Bold">Duration of Effect</span><br><br></p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">This subsection applies specifically to vaccines and should describe the duration of effect of the recommended dose (e.g., duration of detectable levels of antibodies and/or conferred immunity status). </p></td></tr></tbody></table><p xmlns="">[text]</p><br xmlns=""><p xmlns=""><span class="Bold">Special Populations and Conditions</span><br>[text]<br></p><ul xmlns=""><li><span class="Bold">Pediatrics </span>[text]</li><li><span class="Bold">Geriatrics </span>[text]</li><li><span class="Bold">Sex </span>[text]</li><li><span class="Bold">Pregnancy and Breast-feeding  </span>[text]</li><li><span class="Bold">Genetic Polymorphism </span>[text]</li><li><span class="Bold">Ethnic Origin </span>[text]</li><li><span class="Bold">Hepatic Insufficiency </span>[text]</li><li><span class="Bold">Renal Insufficiency </span>[text]</li><li><span class="Bold">Obesity </span>[text]</li></ul></div></div><div class="Section" data-sectionCode="pi11" id="da324d26-c939-443a-901e-526dcc314522"><a name="cc0d2dd9-1c53-49dc-bad3-d6b420d069e9"> </a><a name="section-6.11"> </a><p></p><h2 xmlns="">11 STORAGE, STABILITY AND DISPOSAL</h2><p xmlns="" class="First">[text]</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">Include recommended storage conditions for each dosage form as supported by stability studies.</p><br><p>For reconstituted products, including parenterals, the recommended storage period and conditions should be stated.</p><br><p>Disposal instructions should be included for all drug products. Include a cross-reference to more detailed safe disposal instructions under 12 SPECIAL HANDLING INSTRUCTIONS where appropriate.</p><br><p>For radiopharmaceutical kits include the following or similar statement: </p><br><p><span class="Italics">Do not use the kit beyond the expiration date stamped on the box. After preparation [product] should be stored at room temperature until administration, within [x] hours of radiolabelling.</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pi12" id="bba325d26-c939-443a-901e-526dcc314522"><a name="fc0d2dd9-1c53-49dc-bad3-d6b420d064e9"> </a><a name="section-6.12"> </a><p></p><h2 xmlns="">12 SPECIAL HANDLING INSTRUCTIONS</h2><p xmlns="" class="First">[text]</p></div></div></div></div><div class="card mb-2 pb-2" id="d91389e0-c234-44d9-8327-91b121723a8f"><h5 class="card-header text-white bg-aurora-accent1">PART II: SCIENTIFIC INFORMATION</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="pii00" id="ab6a947eb-e2be-45c0-8b2e-15d0d0eebed8"><a name="d91389e0-c234-44d9-8327-91b121723a8f"> </a><a name="section-7"> </a><p></p><h1 xmlns="">PART II: SCIENTIFIC INFORMATION</h1><div class="Section" data-sectionCode="pii13" id="ee2875272-8229-4c12-919e-827854dcd76a"><a name="d134d52c-f9d4-4698-a082-84b29ee3d95a"> </a><a name="section-7.1"> </a><p></p><h2 xmlns="">13 PHARMACEUTICAL INFORMATION</h2><p xmlns="" class="First"><span class="Bold">Drug
                                    Substance</span></p><p xmlns="">Proper name:  [text]</p><p xmlns="">Chemical name:  [text]</p><p xmlns="">Molecular formula and molecular mass:  [text]</p><p xmlns="">Structural formula:  [image]<br><img alt="chemical structure" src="structure.jpg"></p><p xmlns="">Physicochemical properties:  [text]</p><p xmlns="">Pharmaceutical standard: [for biologics] [text]</p><p xmlns=""><span class="Bold">Product Characteristics:</span></p><p xmlns="">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For radiopharmaceuticals, provide detailed information or a lengthier description of product characteristics that are in addition to those mentioned under 6.1 Physical Characteristics.</p><br><p>For biologics, this subsection should describe the method of manufacture. Sponsors are not expected to supply proprietary information, but they must provide enough detail to provide health professionals with an understanding of how the product is prepared.</p></td></tr></tbody></table><p xmlns=""><span class="Bold">Viral Inactivation</span></p><p xmlns="">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For products derived from plasma, detail the viral reduction steps. Include information on selection criteria for donors, if applicable.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pii14" id="ab2875272-8229-4c12-919e-827854ddd76a"><a name="c134d52c-f9d4-4698-a082-84b29ee3d95a"> </a><a name="section-7.2"> </a><p></p><h2 xmlns="">14 CLINICAL TRIALS</h2><div class="Section" data-sectionCode="pii14.1" id="a2875272-8229-4c12-919e-827854ddd78a"><a name="e134d52c-f9d4-4698-a082-84b29ee3d95a"> </a><a name="section-7.2.1"> </a><p></p><h3 xmlns="">14.1 Trial Design and Study Demographics</h3><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For biosimilars, include the following or similar statement for comparative trials: </p><br><p><span class="Italics">Clinical studies conducted to support similarity between [Biosimilar brand name] and the reference biologic drug included:</span></p><ul><li>[text] [Provide a general description of study 1, for example, a randomized comparative bioavailability study performed in healthy volunteers.]</li><li>[text] [Provide a general description of study 2, for example, a double-blind, randomized, comparative safety and efficacy study performed in patients with moderate to severe rheumatoid arthritis.]</li></ul></td></tr></tbody></table><a xmlns="" name="t14.1"></a><table xmlns="" width="100%" style="border: solid thin; border-color: #CCCCCC;" rules="all" frame="border"><caption><span>Table [#] - Summary of patient demographics for
                                                clinical trials in [specific indication]</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Study #</th><th class="Botrule Lrule Rrule Toprule">Study design</th><th class="Botrule Lrule Rrule Toprule">Dosage, route of administration and
                                                  duration</th><th class="Botrule Lrule Rrule Toprule">Study subjects (n)</th><th class="Botrule Lrule Rrule Toprule">Mean age (Range)</th><th class="Botrule Lrule Rrule Toprule">Sex</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td></tr></tbody></table><p xmlns="" class="First">[Provide a brief narrative describing the
                                            demographic characteristics of the study
                                            population:]<br>[text]</p></div><div class="Section" data-sectionCode="pii14.2" id="a2875272-8229-4a12-919e-827854ddd78a"><a name="a134d52c-f9d4-4698-a082-84b29ee3d95a"> </a><a name="section-7.2.2"> </a><p></p><h3 xmlns="">14.2 Study Results</h3><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For biosimilars, there should be no claims of bioequivalence or clinical equivalence between the biosimilar and the reference biologic drug. For biosimilar submissions that include only comparative bioavailability studies, leave this section blank and include the following statement:</p><br><p><span class="Italics">See 14.3 Comparative Bioavailability Studies.</span></p></td></tr></tbody></table><a xmlns="" name="t14.2"></a><table xmlns="" width="100%" style="border: solid thin; border-color: #CCCCCC;" rules="all" frame="border"><caption><span>Table [#] - Results of study [#] in [specific
                                                indication]</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule">Primary Endpoints</th><th class="Botrule Lrule Rrule Toprule">Associated value and statistical significance
                                                  for Drug at specific dosages</th><th class="Botrule Lrule Rrule Toprule">Associated value and statistical significance
                                                  for Placebo or active control</th></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td><td class="Botrule Lrule Rrule Toprule">[text]</td></tr></tbody></table></div><div class="Section" data-sectionCode="pii14.3" id="df2875272-8229-4c12-919e-827954ddd78a"><a name="c134d52c-f9d4-4698-a012-84b29ee3d95a"> </a><a name="section-7.2.3"> </a><p></p><h3 xmlns="">14.3 Comparative Bioavailability Studies</h3><p xmlns="" class="First">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Provide a narrative outlining the design of the bioequivalence study. The values in the table should be based on the measured data from the study. No potency correction should be applied.</p><br><p>For biosimilars, comparative pharmacokinetic (PK) studies should be conducted to rule out differences in PK characteristics between the biosimilar and the reference biologic drug. For clinical studies conducted to support similarity between a biosimilar and the reference biologic drug, there may be cases where a pharmacodynamic (PD) marker may be used in lieu of clinical endpoints or as additional support for similarity. If this is the case, include a brief narrative describing the study and a tabulation of the PD results including the appropriate statistical analyses.</p></td></tr></tbody></table><a xmlns="" name="t14.3"></a><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" rules="all" frame="border" width="100%"><caption><span>Table for single dose studies</span></caption><tfoot><tr><td colspan="0" align="left"><dl class="Footnote"><dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt><dd>Identity of the test
                                                  product.</dd><dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt><dd>Identity of the reference
                                                  product, including the manufacturer, and origin
                                                  (country of purchase).</dd><dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt><dd>Indicate %
                                                  Confidence Interval (i.e., 90% or 95%) in the
                                                  column heading and list for the AUC<span class="Sub">T</span>,
                                                  AUC<span class="Sub">I</span> and C<span class="Sub">MAX</span> (if
                                                  required).</dd><dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt><dd>For drugs with
                                                      a half-life greater than 24 hours AUC<span class="Sub">T</span> should be
                                                  replaced with AUC<span class="Sub">0-72</span>.</dd><dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt><dd>Expressed as
                                                  either the arithmetic mean (CV%) or the median
                                                  (range) only.</dd><dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt><dd>Expressed as the
                                                  arithmetic mean (CV%) only.</dd></dl></td></tr></tfoot><tbody class="Headless"><tr class="First" align="center"><th class="Botrule Lrule Rrule Toprule" colspan="5">Analyte
                                                  Name<br>(__x__mg)<br>From measured
                                                  data<br>Geometric Mean<br>Arithmetic Mean
                                                  (CV %)</th></tr><tr><th class="Botrule Lrule Rrule Toprule">Parameter</th><th class="Botrule Lrule Rrule Toprule">Test<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></th><th class="Botrule Lrule Rrule Toprule">Reference<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></th><th class="Botrule Lrule Rrule Toprule">% Ratio of Geometric Means</th><th class="Botrule Lrule Rrule Toprule">Confidence Interval<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></th></tr><tr><td class="Botrule Lrule Rrule Toprule">AUC<span class="Sub">T</span> (units)<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">AUC<span class="Sub">I</span> (units)</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">C<span class="Sub">MAX</span> (units)</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">T<span class="Sub">MAX</span> (h)<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule">Not applicable</td><td class="Botrule Lrule Rrule Toprule">Not applicable</td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">T<span class="Sub">1/2</span> (h)<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule">Not applicable</td><td class="Botrule Lrule Rrule Toprule">Not applicable</td></tr></tbody></table><a xmlns="" name="t14.3m"></a><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" rules="all" frame="border" width="100%"><caption><span>Table for multiple dose studies</span></caption><tfoot><tr><td colspan="0" align="left"><dl class="Footnote"><dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt><dd>Identity of the test
                                                  product.</dd><dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt><dd>Identity of the reference
                                                  product, including the manufacturer, and origin
                                                  (country of purchase),where
                                                  applicable.</dd><dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt><dd>Indicate %
                                                  Confidence Interval (i.e., 90% or 95%) in the
                                                  column heading and list for the AUC<span class="Sub">T</span>,
                                                  AUC<span class="Sub">I</span> and C<span class="Sub">MAX</span> (if
                                                  required).</dd><dt><a name="footnote-10" href="#footnote-reference-10">§</a></dt><dd>Expressed as
                                                  either the arithmetic mean (CV%) or the median
                                                  (range) only.</dd></dl></td></tr></tfoot><tbody class="Headless"><tr class="First" align="center"><th class="Botrule Lrule Rrule Toprule" colspan="5">Analyte
                                                  Name<br>(__x__mg)<br>From measured
                                                  data<br>Geometric Mean<br>Arithmetic Mean
                                                  (CV %) </th></tr><tr><th class="Botrule Lrule Rrule Toprule">Parameter</th><th class="Botrule Lrule Rrule Toprule">Test<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></th><th class="Botrule Lrule Rrule Toprule">Reference<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a></th><th class="Botrule Lrule Rrule Toprule">% Ratio of Geometric Means</th><th class="Botrule Lrule Rrule Toprule">Confidence Interval<a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a></th></tr><tr><td class="Botrule Lrule Rrule Toprule">AUC<span class="Sub">tau</span> (units)</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">C<span class="Sub">MAX</span> (units)</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">C<span class="Sub">MIN</span> (units)</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">T<span class="Sub">MAX</span> (h)<a name="footnote-reference-10" href="#footnote-10" class="Sup">§</a></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule">Not applicable</td><td class="Botrule Lrule Rrule Toprule">Not applicable</td></tr></tbody></table></div><div class="Section" data-sectionCode="pii14.4" id="bba325d26-c939-443a-901e-526ddc314522"><a name="fc0d2dd9-1c53-a9dc-bad3-d6b420d064e9"> </a><a name="section-7.2.4"> </a><p></p><h3 xmlns="">14.4 Immunogenicity</h3><p xmlns="" class="First">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For vaccines, include information on efficacy by class of individuals, to recognize differences in immunogenicity. </p><br><p>For biosimilars, include comparative immunogenicity results, if applicable, with a brief narrative describing the testing strategy for anti-drug antibodies (ADA) and the overall incidence of treatment emergent or treatment enhanced confirmed binding antibodies.</p><br><p>The following or similar statements may be included:</p><br><p><span class="Italics">Comparing the incidences of antibodies between studies or between products may be misleading due to differences in the types, sensitivities and/or specificities of the assays employed.</span></p><br><p>or</p><br><p><span class="Italics">As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pii14.5" id="b7a325d26-c939-443a-901e-526ddc314522"><a name="fc0d2ad9-1c53-a9dc-bad3-d6b420d064e9"> </a><a name="section-7.2.5"> </a><p></p><h3 xmlns="">14.5 Clinical Trials - Reference Biologic Drug</h3><p xmlns="" class="First">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For biosimilars only, otherwise delete this subheading. Import the clinical trial information that appears in the reference biologic drug’s monograph with respect to indications to be authorized for the biosimilar. Clinical trial data for indications that will not be authorized for the biosimilar should not be included.</p></td></tr></tbody></table></div></div><div class="Section" data-sectionCode="pii15" id="a2875272-8229-4c12-a19e-827954ddd78a"><a name="e134e52c-f1d4-4798-a082-84b29ee3d95a"> </a><a name="section-7.3"> </a><p></p><h2 xmlns="">15 MICROBIOLOGY</h2><p xmlns="" class="First">[text]<br>[table]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For drugs with no antimicrobial properties, include the following statement:</p><br><p><span class="Italics">No microbiological information is required for this drug product.</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pii16" id="a42a7572-8229-4c12-a19e-827954ddd78a"><a name="c134d52c-f9d4-4698-a082-84b29ee3a95a"> </a><a name="section-7.4"> </a><p></p><h2 xmlns="">16 NON-CLINICAL TOXICOLOGY</h2><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Only use a table if presentation will be more concise. The following or similar statements should be included where applicable:</p><br><p><span class="Italics">No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether [Brand name] affects fertility in males or females.</span></p><br><p><span class="Italics">As with other radiopharmaceuticals which distribute intracellularly, there may be increased risk of chromosome damage from Auger electrons if nuclear uptake occurs.</span></p><br><p>For biologics, this section should confirm if long-term studies have been done to evaluate immunogenicity.</p><br><p>For biosimilars, include toxicology information that appears in the reference biologic drug product monograph. The reference biologic drug brand name should be changed to the proper name (INN). Data that relates only to indications that will not be authorized for the biosimilar should not be included.</p></td></tr></tbody></table><p xmlns="" class="First"><span class="Bold">General Toxicology: </span>[text]</p><p xmlns=""><span class="Bold">Carcinogenicity: </span>[text]</p><p xmlns=""><span class="Bold">Genotoxicity: </span>[text]</p><p xmlns=""><span class="Bold">Reproductive and Developmental Toxicology: </span>[text]</p><p xmlns=""><span class="Bold">Special Toxicology: </span>[text]</p><p xmlns=""><span class="Bold">Juvenile Toxicity: </span>[text]</p><div class="Section" data-sectionCode="pii16.1" id="a2875272-8229-4c12-a19e-8279549dd78a"><a name="e124d52c-f2d4-4698-a082-84b29ee3d95a"> </a><a name="section-7.4.1"> </a><p></p><h3 xmlns="">16.1 Comparative Non-Clinical Pharmacology and Toxicology</h3><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">For biosimilars only, otherwise delete this subheading, as well as 16.1.1 Comparative Non-Clinical Pharmacodynamics and 16.1.2. Comparative Toxicology.</p></td></tr></tbody></table><div class="Section" data-sectionCode="pii16.1.1" id="a2875272-8229-4c12-a19e-8279749dd78a"><a name="e134a52c-f1d4-4698-a182-84b29ee3d95a"> </a><a name="section-7.4.1.1"> </a><p></p><h4 xmlns="">16.1.1 Comparative Non-Clinical Pharmacodynamics</h4><p xmlns="" class="First"><span class="Bold">In vitro Studies</span><br>[provide a narrative and/or table]<br>[text]<br>[table]</p></div><div class="Section" data-sectionCode="pii16.1.2" id="a2875212-8229-4c12-a19e-8279749dd78a"><a name="e184a52c-f1d4-4698-a082-84b29ee3d95a"> </a><a name="section-7.4.1.2"> </a><p></p><h4 xmlns="">16.1.2 Comparative Toxicology</h4><p xmlns="" class="First">[provide a narrative and/or table]<br>[text]<br>[table]</p></div></div></div><div class="Section" data-sectionCode="pii17" id="ef8a4d48-0fc3-4e44-b4b6-550140d4de5d"><a name="be74b6e6-c431-4a5f-a18e-ed3214381456"> </a><a name="section-7.5"> </a><p></p><h2 xmlns="">17 SUPPORTING PRODUCT MONOGRAPHS</h2><p xmlns="" class="First">[numbered list:]</p><p xmlns="">[Brand name] [dosage form, strength], submission control [number], Product Monograph, [Sponsor]. [(MON, DD, YYYY)] </p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">List only Health Canada authorized product monographs that were supportive in the development of the product monograph (e.g., Canadian Reference Product for a generic, or Reference Biologic Drug for a biosimilar biologic drug), combination product, or subsequent entry product.</p><br><p>Where there are no such supporting product monographs, this section, including heading, should be omitted.</p></td></tr></tbody></table></div></div></div></div><div class="card mb-2 pb-2" id="be74b6e6-c461-4a5f-a18e-ed321b381456"><h5 class="card-header text-white bg-aurora-accent1">PATIENT MEDICATION INFORMATION</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="pmi00" id="baa4d498-0fc3-4e44-b4b6-550140d4de5d"><a name="be74b6e6-c461-4a5f-a18e-ed321b381456"> </a><a name="section-8"> </a><p></p><h1 xmlns="">PATIENT MEDICATION INFORMATION</h1><div class="Section" data-sectionCode="pmi01" id="ea4ec98b-b2d3-4d73-877c-aaa5eb28997d"><a name="067c0a3b-5869-43a7-baff-ce6de72ae1e5"> </a><a name="section-8.1"> </a><p></p><h2 xmlns="">READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE</h2><p xmlns="" class="First"><span class="Bold">[Brand
                                    name]</span></p><p xmlns=""><span class="Bold">[Proper Name in Final Dosage
                                        Form]</span></p><p xmlns="">Read this carefully before you start taking <span class="Bold">[Brand name]</span> and each time you
                                    get a refill. This leaflet is a summary and will not tell you
                                    everything about this drug. Talk to your healthcare professional
                                    about your medical condition and treatment and ask if there is
                                    any new information about <span class="Bold">[Brand
                                        name]</span>.</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">For biosimilars include the following statement: <br><br><span class="Italics"><span class="Bold">[Brand name]</span> is a biosimilar biologic drug (biosimilar) to the reference biologic drug [Reference biologic drug brand name]. A biosimilar is authorized based on its similarity to a reference biologic drug that was already authorized for sale. 
                                                </span></td></tr></tbody></table><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" frame="border"><tbody class="Headless"><tr class="First"><td align="center"><span class="Bold">Serious Warnings and
                                                  Precautions</span></td></tr><tr class="Last"><td><ul><li>[text]</li><li>[text]</li></ul></td></tr></tbody></table><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" frame="border"><tbody class="Headless"><tr class="First Last"><td><p class="First">The box should contain a plain language version of the information provided in 3 SERIOUS WARNINGS AND PRECAUTIONS BOX. Delete this box if there are no Serious Warnings and Precautions.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi02" id="baa4d498-0gc3-4e44-bcb6-550140d4de5d"><a name="be74b6e6-1431-4a5f-a18e-ed321b381456"> </a><a name="section-8.2"> </a><p></p><h2 xmlns="">What is [Brand name] used for?</h2><ul xmlns=""><li>[text]</li><li>[text]</li></ul><p xmlns="" class="First">[For products that have been authorized under the Notice of Compliance with Conditions (NOC/c) policy, include the following boxed statement:]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br>
                                                "For the following indication(s) [Brand name] has been approved with conditions (NOC/c). This means it has passed Health Canada’s review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the drug works the way it should. For more information, talk to your healthcare professional."
                                                <br>
                                                [Provide a bullet listing of the indications from Part I.]
                                                <ul><li>[text]</li></ul>
                                                [If the Indications section includes lifestyle recommendations as part of the therapy, they should be included here.]<br>
                                                "For the following indication(s) [Brand name] has been approved without conditions. This means it has passed Health Canada’s review and can be bought and sold in Canada."
                                                <br>
                                                [Provide a bullet listing of the indications from Part I.]
                                                <ul><li>[text]</li></ul>
                                                [If the Indications section includes lifestyle recommendations as part of the therapy, they should be included here.]
                                                
                                            </td></tr></tbody></table><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><br><p class="First">For products that have been authorized under the NOC/c policy, the following text must be included:</p><br><p><span class="Italics"><span class="Bold">What is a Notice of Compliance with Conditions (NOC/c)?</span></span></p><br><p><span class="Italics">A Notice of Compliance with Conditions (NOC/c) is a type of approval to sell a drug in Canada.</span></p><br><p><span class="Italics">Health Canada only gives an NOC/c to a drug that treats, prevents, or helps identify a serious or life-threatening illness. The drug must show promising proof that it works well, is of high quality, and is reasonably safe. Also, the drug must either respond to a serious medical need in Canada, or be much safer than existing treatments.</span></p><br><p><span class="Italics">Drug makers must agree in writing to clearly state on the label that the drug was given an NOC/c, to complete more testing to make sure the drug works the way it should, to actively monitor the drug’s performance after it has been sold, and to report their findings to Health Canada.</span></p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi03" id="bca4d498-0gc3-4e44-bcb6-550140d4de5d"><a name="be74b6e6-c431-4adf-a18e-ed321b381456"> </a><a name="section-8.3"> </a><p></p><h2 xmlns="">How does [Brand name] work?</h2><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pmi04" id="bca4d498-0gc3-4e44-bcb6-55013024de5d"><a name="be74b6e6-c431-4a5f-a18e-ed321b381756"> </a><a name="section-8.4"> </a><p></p><h2 xmlns="">What are the ingredients in [Brand name]?</h2><p xmlns="" class="First">Medicinal ingredients: [List all medicinal ingredients]<br>Non-medicinal ingredients: [List all
                                    non-medicinal ingredients in alphabetical order.]</p></div><div class="Section" data-sectionCode="pmi05" id="bca4d498-0gc3-4e54-bcb6-550130d4de5d"><a name="be74b6e6-c431-4a5f-a18e-ed3a1b381456"> </a><a name="section-8.5"> </a><p></p><h2 xmlns="">[Brand name] comes in the following dosage forms:</h2><p xmlns="" class="First">[dosage form(s) and strength(s)]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
                                                To maintain brevity, this is the only information required in this section.                                              
                                            </td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi06" id="bca4c498-00c3-4e44-bcb6-550134d4de5d"><a name="be74b6e6-cd31-4a5f-a18e-ed321b381456"> </a><a name="section-8.6"> </a><p></p><h2 xmlns="">Do not use [Brand name] if:</h2><ul xmlns=""><li>[text]</li><li>[text]</li></ul><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
                                                [Enter one point for each contraindication from 2 CONTRAINDICATIONS.                                              
                                            </td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi07" id="b6b37351-bbc9-46d9-b148-27ba3cb0a75e"><a name="be74b6e6-c431-4a5f-a18e-ed32cc381456"> </a><a name="section-8.7"> </a><p></p><h2 xmlns="">To help avoid side effects and ensure proper use, talk to your
                                healthcare professional before you take [Brand name]. Talk about any
                                health conditions or problems you may have, including if
                                you:</h2><ul xmlns=""><li>[text]</li><li>[text]</li></ul><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
                                                Enter one point for each item listed in 7 WARNINGS AND PRECAUTIONS.                                              
                                            </td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi08" id="edac0d6f-3c91-48b5-99c0-e0f940925d37"><a name="be74bbe6-c431-4a5f-a18e-ed321b381456"> </a><a name="section-8.8"> </a><p></p><h2 xmlns="">Other warnings you should know about:</h2><p xmlns="" class="First">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
                                                Enter general information that would not appear in the Serious Warnings and Precautions Box or other existing headings. Otherwise this heading is not required.                                              
                                            </td></tr></tbody></table><p xmlns=""><span class="Bold">Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.</span></p></div><div class="Section" data-sectionCode="pmi09" id="bca4c498-0ac3-4e44-bcb6-550134d4de5d"><a name="be74b6e6-c431-4a5f-a18e-ed321ab81456"> </a><a name="section-8.9"> </a><p></p><h2 xmlns="">The following may interact with [Brand name]:</h2><ul xmlns=""><li>[list]</li></ul><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
                                                Include information from 9 DRUG INTERACTIONS. If no relevant interactions are known, add a statement to reflect this.                                             
                                            </td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi10" id="e23321cd-5111-4aa3-b650-74f93bcda261"><a name="be74b6e6-c431-4a5f-a18e-ed3212281456"> </a><a name="section-8.10"> </a><p></p><h2 xmlns="">How to take [Brand name]:</h2><ul xmlns=""><li>[text]</li></ul><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
                                                Consider the following or similar statements as required:<br><br><span class="Italics">Do not use this medication if it looks cloudy or is leaking.</span><br>
                                                or<br><span class="Italics">[Brand name] will be given to you by a healthcare professional in a healthcare setting.
                                                    or, for radiopharmaceuticals:
                                                </span><br><span class="Italics">[product] will be given to you by a healthcare professional who is experienced in the use of radiopharmaceuticals.</span></td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi11" id="cd0892a2-0e32-4fb7-9cc9-1bbfff60dee7"><a name="be74b6e6-c431-4a5f-a18e-11321b381456"> </a><a name="section-8.11"> </a><p></p><h2 xmlns="">Usual dose:</h2><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pmi12" id="beaaa5b8-6693-4d4c-a897-fa5c9562b1be"><a name="be74b6e6-c431-4a5f-a18e-ed321b311456"> </a><a name="section-8.12"> </a><p></p><h2 xmlns="">Overdose:</h2><p xmlns="" class="First">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">If you think
                                                you have taken too much [Brand name], contact your
                                                healthcare professional, hospital emergency
                                                department or regional poison control centre
                                                immediately, even if there are no symptoms.</td></tr></tbody></table><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">From 5 OVERDOSAGE, provide information on what to do if the individual has taken too much medication. The boxed message may be modified to provide the most appropriate advice according to current standards of care for this drug product.</td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi13" id="ffd59b8d-fe66-4d86-a54f-0613d4168199"><a name="be74b6e6-c431-4a5f-a18e-ed321e381456"> </a><a name="section-8.13"> </a><p></p><h2 xmlns="">Missed dose:</h2><p xmlns="" class="First">[text]</p></div><div class="Section" data-sectionCode="pmi14" id="cb61f530-b95a-4047-b8ea-861c5a7a05e8"><a name="be74b6e6-c431-4a5f-a98e-ed321b381456"> </a><a name="section-8.14"> </a><p></p><h2 xmlns="">What are possible side effects from using [Brand name]?</h2><p xmlns="" class="First">These are not all the possible side effects you may feel
                                    when taking [Brand name]. If you experience any side effects not
                                    listed here, contact your healthcare professional.</p><p xmlns="">[text]</p><table xmlns="" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">Self-limiting side effects should be described in the text section only. Those listed in 3 SERIOUS WARNINGS AND PRECAUTIONS BOX must be listed in the serious side effects table.  Each side effect should appear only once, in text or in the table to avoid duplication.</td></tr></tbody></table><a xmlns="" name="tpmi14"></a><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" border="1" rules="all" frame="border" width="100%"><caption><span>Serious side effects and what to do about
                                        them</span></caption><tbody class="Headless"><tr class="First"><th class="Botrule Lrule Rrule Toprule" rowspan="2">Symptom / effect</th><th class="Botrule Lrule Rrule Toprule" colspan="2" align="center">Talk to your healthcare
                                                professional</th><th class="Botrule Lrule Rrule Toprule" rowspan="2">Stop taking drug and get immediate
                                                medical help</th></tr><tr><th class="Botrule Lrule Rrule Toprule">Only if severe</th><th class="Botrule Lrule Rrule Toprule">In all cases</th></tr><tr><td class="Botrule Lrule Rrule Toprule"><span class="Bold">VERY COMMON</span><br></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">[Condition: symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">[Condition: symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule"><span class="Bold">COMMON</span><br></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">[Condition: symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">[Condition: symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule"><span class="Bold">RARE</span><br></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr><td class="Botrule Lrule Rrule Toprule">[Condition: symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">[Condition: symptom / effect]</td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td><td class="Botrule Lrule Rrule Toprule"></td></tr></tbody></table><p xmlns="">If you have a troublesome symptom or side effect that is
                                    not listed here or becomes bad enough to interfere with your
                                    daily activities, talk to your healthcare
                                    professional.</p><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Reporting Side
                                                  Effects</span><br>You can report any suspected
                                                  side effects associated with the use of health
                                                  products to Health Canada by:</p><br><ul class="Unordered"><li>Visiting the Web page on Adverse Reaction
                                                  Reporting <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html">(https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html)</a>
                                                  for information on how to report online, by mail
                                                  or by fax; or</li><li>Calling toll-free at 1-866-234-2345.</li></ul><p><span class="Italics">NOTE:
                                                  Contact your health professional if you need
                                                  information about how to manage your side effects.
                                                  The Canada Vigilance Program does not provide
                                                  medical advice.</span><br></p></td></tr></tbody></table><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Reporting Suspected Side Effects for Vaccines</span><br><span class="Bold">For the general public: </span>Should you experience a side effect following immunization, please report it to your healthcare professional.</p><br><p>Should you require information related to the management of the side effect, please contact your healthcare professional. The Public Health Agency of Canada, Health Canada and [Sponsor Name] cannot provide medical advice.</p><br><p><span class="Bold">For healthcare professionals: </span>If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory (<a href="http://www.phac-aspc.gc.ca/im/aefi-essi-form-eng.php">http://www.phac-aspc.gc.ca/im/aefi-essi-form-eng.php</a>) and send it to your local Health Unit.</p></td></tr></tbody></table><table xmlns="" style="border: solid thin; border-color: #CCCCCC;" width="100%" rules="all" frame="border"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First">Please choose the reporting box option that is most appropriate for this product.</p></td></tr></tbody></table></div><div class="Section" data-sectionCode="pmi15" id="c9d75711-2ce9-451e-aa51-91026ec1555e"><a name="be74b6e6-c431-4a5f-a18e-ed321b081456"> </a><a name="section-8.15"> </a><p></p><h2 xmlns="">Storage:</h2><p xmlns="" class="First">[text]</p><p xmlns="">Keep out of reach and sight of children.</p></div><div class="Section" data-sectionCode="pmi16" id="f6693e7a-21c9-492f-833b-4e8f3911d3a5"><a name="be74b6e6-c431-4a5f-a18e-ed321b381446"> </a><a name="section-8.16"> </a><p></p><h2 xmlns="">If you want more information about [Brand name]:</h2><ul xmlns=""><li>Talk to your healthcare professional</li><li>Find the full product monograph that is prepared for
                                        healthcare professionals and includes this Patient
                                        Medication Information by visiting the Health Canada website 
                                        <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html">https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html</a>; the
                                        manufacturer's website [website], or by calling 1-800-[phone
                                        number].</li></ul><p xmlns="" class="First">This leaflet was prepared by [Sponsor Name].</p><p xmlns="">Last Revised [MON-DD-YYYY]</p></div></div></div></div><div class="hide-in-screen force-page-break-before card spl" id="print-product-details"><h2>PRODUCT DETAILS</h2><div class="spl"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Market Authorization Holder -&nbsp;</span>Acme Pharma Inc. (1111)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>9526 Columbia St.</td></tr><tr><td>Hanover Park,&nbsp;Illinois,&nbsp;60133</td></tr><tr><td>United States of America (the)</td></tr></table></td><td class="formItem"><div>Tel: +1-202-555-0178</div><div>Email: <a href="mailto:test@canada.ca">test@canada.ca</a></div><div>Web: <a href="http://www.test.ca">http://www.test.ca</a></div></td></tr></table><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Canadian Importer/Distributor -&nbsp;</span>Acme Distributing Ltd. (0000)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>250 Lanark Ave.</td></tr><tr><td>Ottawa,&nbsp;Ontario,&nbsp;K1Z 6R5</td></tr><tr><td>Canada</td></tr></table></td><td class="formItem"><div>Tel: +1-416-555-0134</div><div>Email: <a href="mailto:test.2@canada.ca">test.2@canada.ca</a></div><div>Web: <a href="http://www.test.ca">http://www.test.ca</a></div></td></tr></table><section><div class="Section"><p></p><h2>PRODUCT #1 LORUM IPSUM TABLETS 
		(ACETAMINOPHEN), 		
			
			ACETAMINOPHEN&nbsp;
				100&nbsp;								
			MG&nbsp;
			/ ACEXAMIC ACID&nbsp;
				45&nbsp;								
			MG&nbsp;
			TABLET</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM TABLETS&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM TABLETS</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">12345678</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Oral use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Tablet</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">100&nbsp;								
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>ACEXAMIC ACID</strong> (7IC4BO7D3R)  (ACEXAMIC ACID - 7IC4BO7D3R) </td><td class="formItem">ACEXAMIC ACID (7IC4BO7D3R) </td><td class="formItem">45&nbsp;								
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off white)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">BULLET</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">10mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">NO SCORE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A;45</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem">APPLE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 9: Fixed-Dose Combination - two or more active ingredients combined in a single dosage form</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Increased Thrombolysis [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">ABC-1234<br></td><td class="formItem">30 &nbsp;in&nbsp;1 Bottle<br></td><td class="formItem">APPROVED<br></td><td class="formItem">2017-01-02<br></td><td class="formItem">2018-01-01<br></td></tr><tr class="formTableRow"><th scope="row" class="formItem">2</th><td class="formItem">ABC-6789<br>ABC-5678<br></td><td class="formItem">4 &nbsp;in&nbsp;1 Box<br>10 &nbsp;in&nbsp;1 Blister<br></td><td class="formItem">APPROVED<br><br></td><td class="formItem">2017-01-01<br><br></td><td class="formItem"><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section><div class="Section"><p></p><h2>PRODUCT #2 LORUM IPSUM CAPSULE 
		(ACETAMINOPHEN), 		
			
			ACETAMINOTADALAFIL&nbsp;
				200&nbsp;								
			MG&nbsp;
			/ ACETAMINOPHEN&nbsp;
				50&nbsp;								
			MG&nbsp;
			CAPSULE, HARD</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM CAPSULE&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen capsule, hard</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM CAPSULE</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">45612322</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Oral use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Capsule, hard</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOTADALAFIL</strong> (CTF06O4T7I)  (ACETAMINOTADALAFIL - CTF06O4T7I) </td><td class="formItem">ACETAMINOTADALAFIL (CTF06O4T7I) </td><td class="formItem">200&nbsp;								
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">50&nbsp;								
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off white),&nbsp;RED (dark red)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">DIAMOND</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">8mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">NO SCORE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">L;200</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem">APPLE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 9: Fixed-Dose Combination - two or more active ingredients combined in a single dosage form</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Lysosomal Function Alteration [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">ABC-6789<br>ABC-5678<br></td><td class="formItem">4 &nbsp;in&nbsp;1 Box<br>10 &nbsp;in&nbsp;1 Blister<br></td><td class="formItem">APPROVED<br><br></td><td class="formItem">2017-01-01<br><br></td><td class="formItem"><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section><div class="Section"><p></p><h2>PRODUCT #3 LORUM IPSUM POWDER 
		(ACETAMINOPHEN), 		
			
			ACETAMINOPHEN&nbsp;
				1&nbsp;								
			MG&nbsp;
			POWDER FOR ORAL SOLUTION</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM POWDER&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen powder for oral solution</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM POWDER</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">65432551</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Subcutaneous use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Powder for oral solution</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">1&nbsp;								
			mg&nbsp;in&nbsp;5&nbsp;mL</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (OFF WHITE)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 0: Not a Combination Product</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Lysosomal Function Alteration [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1212<br><br><br></td><td class="formItem">1 &nbsp;in&nbsp;1 Box<br>2 &nbsp;in&nbsp;1 Bag<br>5 mL&nbsp;in&nbsp;1 Vial<br></td><td class="formItem">APPROVED<br><br><br></td><td class="formItem">2018-06-01<br><br><br></td><td class="formItem"><br><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section><div class="Section"><p></p><h2>PRODUCT #4 LORUM IPSUM 
		(ACETAMINOPHEN)</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">61325884</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem"></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1111<br></td><td class="formItem">1 &nbsp;in&nbsp;1 Box<br></td><td class="formItem">APPROVED<br></td><td class="formItem">2017-01-02<br></td><td class="formItem">2018-01-01<br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">APPROVED</td><td class="formItem">2017-10-09</td><td class="formItem"></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Quantity of Parts</td></tr><tr><th scope="col" class="formTitle">Part&nbsp;#</th><th scope="col" class="formTitle">Package Quantity</th><th scope="col" class="formTitle">Total Product Quantity</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>Part&nbsp;1</strong></td><td class="formItem">1 Vial </td><td class="formItem">5&nbsp;mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>Part&nbsp;2</strong></td><td class="formItem">1 Injection syringe </td><td class="formItem">5&nbsp;mL</td></tr></table></td></tr><tr><td><table width="100%" cellspacing="0" cellpadding="5"><tr><td class="contentTableTitle">Part&nbsp;1&nbsp;of&nbsp;2</td></tr><tr><td class="contentTableTitle"><strong>LORUM IPSUM POWDER&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen powder for oral solution</span></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM POWDER</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02490064</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Intravenous use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Powder for oral solution</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">50&nbsp;								
			ug&nbsp;in&nbsp;1&nbsp;mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (OFF WHITE)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 0: Not a Combination Product<br>Type 8: Kit - two or more drug products having separate DINs, or a combination of one or more drug products and non-drug products packaged for use together</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Bisphosphonate [EPC]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1212<br></td><td class="formItem">5 mg&nbsp;in&nbsp;1 Vial<br></td><td class="formItem"><br></td><td class="formItem"><br></td><td class="formItem"><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">218531</td><td class="formItem"></td><td class="formItem"></td><td class="formItem"></td></tr></table></td></tr><tr><td><table width="100%" cellspacing="0" cellpadding="5"><tr><td class="contentTableTitle">Part&nbsp;2&nbsp;of&nbsp;2</td></tr><tr><td class="contentTableTitle"><strong>WATER&nbsp;		
					</strong><br><span class="contentTableReg">sodium chloride, water for injections oral liquid</span></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">WATER</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">Sodium chloride, water for injections</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02490065</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Intravenous use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Oral liquid</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>SODIUM CHLORIDE</strong> (451W47IQ8X)  (SODIUM CHLORIDE - 451W47IQ8X) </td><td class="formItem">SODIUM CHLORIDE (451W47IQ8X) </td><td class="formItem">1&nbsp;								
			mL&nbsp;in&nbsp;1&nbsp;mL</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (Colourless to off white)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem"></td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 1: Prefilled Drug Device/Delivery system (syringe, patch, etc.)</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">OTC</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Blood Pressure Alteration [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">1234<br></td><td class="formItem">4 mL&nbsp;in&nbsp;1 Injection syringe<br></td><td class="formItem"><br></td><td class="formItem"><br></td><td class="formItem"><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">218531</td><td class="formItem"></td><td class="formItem"></td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section><div class="Section"><p></p><h2>PRODUCT #5 LORUM IPSUM CELLS RANGE 
		(ACETAMINOPHEN), 		
			
			ACETAMINOPHEN&nbsp;
				2,000,000&nbsp;-&nbsp;60,000,000&nbsp;								
			CELLS&nbsp;
			SOLUTION FOR INJECTION</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>LORUM IPSUM CELLS RANGE&nbsp;		
					</strong><br><span class="contentTableReg">acetaminophen solution for injection</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">LORUM IPSUM CELLS RANGE</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">acetaminophen</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">12345678</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">Oral use</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">Solution for injection</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ACETAMINOPHEN</strong> (362O9ITL9D)  (ACETAMINOPHEN - 362O9ITL9D) </td><td class="formItem">ACETAMINOPHEN (362O9ITL9D) </td><td class="formItem">2,000,000&nbsp;-&nbsp;60,000,000&nbsp;								
			CELLS</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (EWQ57Q8I5X) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong> (OP1R32D61U) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CROSPOVIDONE</strong> (2S7830E561) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong> (70097M6I30) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong> (15FIX9V2JP) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off white)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">BULLET</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">10mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">NO SCORE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A;45</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem">APPLE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product Type</td><td class="formItem">Type 0: Not a Combination Product</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">USP</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">Prescription</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">Blood Pressure Alteration [PE]</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="6" class="formHeadingTitle">Packaging Status</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Package Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">ABC-1234<br></td><td class="formItem">30 &nbsp;in&nbsp;1 Bottle<br></td><td class="formItem">APPROVED<br></td><td class="formItem">2017-01-02<br></td><td class="formItem">2018-01-01<br></td></tr><tr class="formTableRow"><th scope="row" class="formItem">2</th><td class="formItem">ABC-6789<br>ABC-5678<br></td><td class="formItem">4 &nbsp;in&nbsp;1 Box<br>10 &nbsp;in&nbsp;1 Blister<br></td><td class="formItem">APPROVED<br><br></td><td class="formItem">2017-01-01<br><br></td><td class="formItem"><br><br></td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Product Status</td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Product Regulatory Status</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">SNDS</td><td class="formItem">123456</td><td class="formItem">APPROVED</td><td class="formItem">2017-01-01</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section></div></div></div></div></div></main></div></div><div id="btnTopDiv" class="hide-in-print"><a id="btnTop" class="btn btn-warning btn-circle btn-md text-white" role="button"><i class="fa fa-arrow-up fa-3x"></i></a></div>
<script src="https://code.jquery.com/jquery-3.4.1.slim.min.js" integrity="sha384-J6qa4849blE2+poT4WnyKhv5vZF5SrPo0iEjwBvKU7imGFAV0wwj1yYfoRSJoZ+n" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/popper.js@1.16.0/dist/umd/popper.min.js" integrity="sha384-Q6E9RHvbIyZFJoft+2mJbHaEWldlvI9IOYy5n3zV9zzTtmI3UksdQRVvoxMfooAo" crossorigin="anonymous"></script>
<script src="https://stackpath.bootstrapcdn.com/bootstrap/4.4.1/js/bootstrap.min.js" integrity="sha384-wfSDF2E50Y2D1uUdj0O3uMBJnjuUD4Ih7YwaYd1iqfktj0Uod8GCExl3Og8ifwB6" crossorigin="anonymous"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/stickyfill/2.0.5/stickyfill.min.js"></script>
		<script xmlns="http://www.w3.org/1999/xhtml">
			try {
			  var elements = document.querySelectorAll('.sticky');
			  Stickyfill.add(elements);
			} catch (e) {
			  console.log(e)
			}			
			
			/* jump to top of form unscrolls left and right side and then scrolls the header into view */
			$(document).ready(function(){
				$("#btnTop").on("click", function(){
					document.getElementById('content').scrollIntoView(true);
					document.getElementById('navigation-scrollbar').scrollTop=0;
					document.getElementById('header').scrollIntoView(true);
					});
			});			
			
			// Mitigate IE/Edge bug showing bullets on lists which are hidden when loading the page
			$(document).ready(function(){
				if (document.documentMode || /Edge/.test(navigator.userAgent)) {
					$('ul:hidden').each(function(){
						$(this).parent().append($(this).detach());
					});
				}				
			});			
		</script></body></html>